Novel insights into the function and regulation of group X secretory phospholipase A\u3csub\u3e2\u3c/sub\u3e by Layne, Joseph D, Jr
University of Kentucky 
UKnowledge 
Theses and Dissertations--Nutritional Sciences Nutritional Sciences 
2013 
Novel insights into the function and regulation of group X 
secretory phospholipase A2 
Joseph D. Layne Jr 
University of Kentucky, jdlayn3@uky.edu 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Layne, Joseph D. Jr, "Novel insights into the function and regulation of group X secretory phospholipase 
A2" (2013). Theses and Dissertations--Nutritional Sciences. 10. 
https://uknowledge.uky.edu/nutrisci_etds/10 
This Doctoral Dissertation is brought to you for free and open access by the Nutritional Sciences at UKnowledge. It 
has been accepted for inclusion in Theses and Dissertations--Nutritional Sciences by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained and attached hereto needed written 
permission statements(s) from the owner(s) of each third-party copyrighted matter to be 
included in my work, allowing electronic distribution (if such use is not permitted by the fair use 
doctrine). 
I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive 
and make accessible my work in whole or in part in all forms of media, now or hereafter known. 
I agree that the document mentioned above may be made available immediately for worldwide 
access unless a preapproved embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s dissertation 
including all changes required by the advisory committee. The undersigned agree to abide by 
the statements above. 
Joseph D. Layne Jr, Student 
Dr. Nancy Webb, Major Professor 
Dr. Howard Glauert, Director of Graduate Studies 
 
 
 
 
 
 
 
 
NOVEL INSIGHTS INTO THE FUNCTION AND REGULATION OF GROUP X 
SECRETORY PHOSPHOLIPASE A2 
 
 
 
 
_________________________________________________ 
DISSERTATION 
_________________________________________________ 
A dissertation submitted in partial fulfillment of the  
requirements for the degree of Doctor of Philosophy in the  
Graduate Center for Nutritional Sciences 
at the University of Kentucky 
 
 
 
 
By 
Joseph D. Layne Jr. 
Lexington, KY 
Director: Dr. Nancy R Webb, PhD 
Lexington, KY 
2013 
Copyright © Joseph D. Layne Jr. 2013 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
NOVEL INSIGHTS INTO THE FUNCTION AND RGULATION OF GROUP X 
SECRETORY PHOSPOLIPASE A2 
 
 Group X secretory phospholipase A2 (GX sPLA2) hydrolyzes membrane 
phospholipids producing free fatty acids and lysophospholipids. Previous studies from 
our lab suggest that mice with targeted deletion of GX sPLA2 (GX KO) have increased 
age-related weight gain due to an increase in overall adiposity. Paradoxically, this 
increased adiposity is associated with improved age-related glucose intolerance. GX KO 
mice also demonstrate a reduced inflammatory response to lipopolysaccharide injection. 
In vitro studies indicate this phenotype may be attributable to blunted macrophage 
mediated inflammatory responses. Given the role of macrophages in promoting adipose 
tissue (AT) inflammation and metabolic dysfunction in response to diet-induced obesity, 
we hypothesized that GX KO mice would be protected from the obesity related metabolic 
derangements associated with overfeeding. Unexpectedly, GX KO mice were only 
partially protected from high fat (HFD) diet-induced glucose intolerance and showed no 
improvement in HFD-induced insulin resistance. Moreover, GX KO mice were not 
protected against HFD-induced AT inflammation.  
GX sPLA2 is produced as a proenzyme (pro-GX sPLA2), and propeptide cleavage 
is required for enzymatic activity. Furin-like proprotein convertases (PCs) have recently 
been implicated in the proteolytic activation of pro-GX sPLA2; however the identity of 
individual PCs involved is unclear. Previous findings from our lab have shown that GX 
sPLA2 is expressed in the adrenals where it regulates glucocorticoid production. GX KO 
mice have increased plasma corticosterone levels under both basal and ACTH-induced 
stress conditions. However, how GX sPLA2 is regulated in the adrenals is still uncertain. 
We hypothesized that PCs may be involved in the proteolytic activation of pro-GX 
sPLA2 in the adrenals. Here we report the novel findings that the PCs, furin and PCSK6, 
proteolytically activate pro-GX sPLA2 in Y1 adrenal cells. Furthermore, we demonstrate 
that PC dependent processing of pro-GX sPLA2 is necessary for GX sPLA2 dependent 
suppression of steroidogenesis. Finally, we provide evidence that pro-GX sPLA2 
processing by PCs is enhanced in response to adrenocorticotropic hormone (ACTH), 
suggesting a novel mechanism for negatively regulating adrenal steroidogenesis. 
Cumulatively, these studies provide valuable insight into the function and regulation of 
GX sPLA2. 
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Chapter 1 
Introduction 
1.1 The secretory phospholipase A2 (sPLA2) family of enzymes 
1.1.1 General properties of sPLA2s 
The phospholipase A2’s are a unique class of enzymes that catalyze the hydrolysis 
of the sn-2 ester bond of glycerophospholipids liberating free fatty acids and 
lysophospholipids. The distinct biochemical properties of PLA2s including cellular 
localization, requirement for Ca2+, substrate specificity, and sequence homology allows 
for classification of these enzymes into several families including the Ca2+ dependent 
arachidonoyl-specific cytosolic (cPLA2), the Ca2+ independent (iPLA2), the platelet-
activating-factor (PAF) hydrolases, and the low molecular weight (~14-18 kDa) secreted 
(sPLA2)1. 
The sPLA2 enzyme family is characterized by their requirement for millimolar 
concentrations of Ca2+, utilization of a highly conserved catalytic histidine within their 
active site, and their ability to hydrolyze phospholipids with distinct polar head groups 
and fatty acyl chains. Thus far, eleven sPLA2 isoforms have been identified (IB, IIA, IIC, 
IID, IIE, IIF, III, V, X, XIIA, and XIIB PLA2-like protein that lacks catalytic activity) 
and placed into different groups based on the number and position of multiple conserved 
cysteine residues which pair up with one another to form disulfide bridges, generating a 
rigid three-dimensional structure (Figure 1.1).  
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The disparity in substrate specificity among the different sPLA2 isoforms is 
attributable to the interfacial binding properties intrinsic to each one. For example, in 
human tears, GIIA sPLA2 is the foremost bactericidal factor against gram-positive 
bacteria2. This may reflect the preference of the highly cationic GIIA sPLA2 for anionic 
phospholipids including phosphatidylserine and phosphatidylglycerol3. Conversely, the 
outer leaflet of mammalian cell membranes are rich in phosphatidylcholine (PtdCho), and 
GIIA sPLA2 exhibits virtually no enzymatic activity toward PtdCho rich liposomes in 
vitro4. GV and GX sPLA2 on the other hand, potently hydrolyze zwitterionic membrane 
phospholipids including PtdCho3,5. This preference for condensed zwitterionic 
phospholipids like those found in mammalian membranes may be due, at least in part, to 
the presence of interfacial tryptophan residues. To this effect, tryptophan-67 in human 
GX sPLA2 is necessary for efficient membrane hydrolysis6. Importantly, GIIA sPLA2 
contains no tryptophan residues and insertion of a unique tryptophan at amino acid 
position 3 (V3W GIIA sPLA2) increased its hydrolytic activity toward PtdCho ~250 
fold7.  
There is now evidence from in vitro studies supporting a role for several sPLA2s 
in the release of arachidonic acid (AA) from cell membranes, thereby providing 
substrates for eicosanoid generation6,8. Among the most potent sPLA2s capable of 
yielding AA is, in descending order, GX, -V, and, -III sPLA2, likely reflecting their 
preference for phosphatidylcholine, the most abundant phospholipid in the outer leaflet of 
mammalian cell membranes5,8,9. Furthermore, there are reports that sPLA2s may also 
indirectly lead to eicosanoid generation through the coordinated activation of cPLA2α. 
Indeed, GV sPLA2 deficiency in bone marrow-derived mast cells (BMMCs) results in the 
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diminished TLR2 dependent generation of eicosanoids, likely due to decreases in the 
sequential phosphorylation and subsequent activation of ERK1/2 and cPLA2α10. On the 
other hand, in mouse spleen cells GX sPLA2 potently releases AA leading to 
prostaglandin E2 (PGE2) production in the presence of Pyrrophenone, a cPLA2α-specific 
inhibitor11.  
1.1.2 sPLA2 functional diversity 
The diversity of tissue distribution and substrate specificity implies broad and 
distinct physiological functions of sPLA2s (Figure 1.1, Table 1.1). To be certain, a role 
for sPLA2s has been defined in regulating physiological processes including digestion of 
dietary phospholipids, inflammation, and host defense against infection among others.    
The first sPLA2 to be identified was GIB sPLA2 in the pancreas12. GIB is secreted 
as a proenzyme into the duodenum by pancreatic acinar cells. Upon propeptide cleavage 
in the gastrointestinal tract by trypsin, GIB is able to digest dietary phospholipids, 
predominantly PtdCho. Mice deficient in GIB sPLA2 are protected against diet-induced 
obesity (DIO) and insulin resistance13. Additional studies went on to suggest that GIB 
sPLA2 deficiency protects mice from diet induced metabolic dysfunction by decreasing 
the absorption of dietary lysophospholipids, and in particular, lysophoshatidylcholine 
(LysoPtdCho)14.  
The investigation into both acute and chronic inflammatory disorders including 
sepsis, rheumatoid arthritis, and atherosclerosis has suggested a role for sPLA2s as 
mediators of the inflammatory response. GIIA sPLA2 is increased in the synovial fluid 
from patients with rheumatoid arthritis15. It has also been shown that GIIA sPLA2 binds 
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integrins alphavbeta3 and alpha4beta1 and induces monocyte proliferation and 
inflammation16, thus making it an attractive target for clinical intervention17. Plasma 
levels of GIIA sPLA2 are increased in patients with sepsis, and appear to correlate with 
the severity of disease18. When antisense oligonucleotides to GIIA sPLA2 are 
administered to Sprague-Dawley rats with sepsis, there is a reduction in overall mortality 
when compared to rats treated with either antibiotics or control oligonucleotides19. When 
the expression of several sPLA2s is examined in rodent models of inflammation, there is 
increased expression of GV sPLA2 and to a lesser extent GIID, IIE, and IIF, in response 
to lipopolysaccharide (LPS) injection20. However, to date, clinical trials using sPLA2 
inhibitors have proven disappointing with respect to their efficacy in treating both sepsis 
and rheumatoid arthritis21-23. Our lab has demonstrated a role for GV sPLA2 in the 
hydrolysis of low density lipoproteins (LDL). GV sPLA2 dependent hydrolysis of LDL 
increases its uptake by macrophages through a mechanism independent of scavenger 
receptors and requiring cell surface proteoglycans24. LDL-R deficient (LDL-R-/-) mice 
overexpressing GV sPLA2 by retrovirus mediated gene transfer have an ~2.7 fold 
increase in lesion area in the aortic root25. Conversely, GV sPLA2 deficiency in bone 
marrow-derived cells (BMCs) results in significantly less lesion formation in LDL-R-/- 
mice when compared to LDL-R-/- mice who received WT BMCs25. Notably, recent 
evidence suggests that plasma sPLA2 may provide prognostic information independent of 
traditional risk markers in patients with coronary artery disease26,27. On the other hand, 
GIID sPLA2 is produced by regulatory T cells (Tregs) where, independent of its catalytic 
activity, it suppresses the proliferation of CD4+ and CD8+ T cells28. Importantly, 
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administration of a GIID-Fc fusion protein inhibits disease development in a mouse 
model of ulcerative colitis28.  
 Several members of the sPLA2 family have been shown to play a role in host 
defense against bacterial infection. The bactericidal properties of several sPLA2s 
including groups I, II, V, X, and XII sPLA2s toward Listeria Monocytogenes has been 
characterized, and bactericidal potency was found to be dependent on the overall positive 
charge, and to a lesser extent, the positive charge within the membrane binding surface of 
the sPLA229. The bactericidal properties of GIIA have been most clearly defined. In vitro 
studies suggest GIIA sPLA2 kills Gram-positive bacteria including staphylococci and 
streptococci30,31.  GIIA sPLA2 has also been found in the mouse intestine, where it was 
shown to kill both Escherichia coli and Listeria monocytogenes32.  
1.1.3 sPLA2 binding proteins 
Several sPLA2s are able to exert physiological affects through means independent 
of their hydrolytic activity. A class of sPLA2 receptors in the brain has been identified 
based on their ability to bind snake venom sPLA2 (OS2) with picomolar level affinity. 
The binding affinity of snake venom sPLA2 for these so-called neuronal-type (N-type) 
receptors appears to strongly correlate with its level of neurotoxicity, with higher affinity 
binding associated with increased toxicity33. Later, another sPLA2 receptor was identified 
in rabbit skeletal muscle and hence named the muscle-type (M-type) receptor34. Through 
the binding of the M-type receptor, GIB sPLA2 is able to influence cell proliferation, 
migration and lipid mediator production35. Additionally, the M-type receptor may be 
involved in GX sPLA2 clearance and degradation36. There is also a soluble form of the 
M-type receptor that may act as an endogenous inhibitor of sPLA2s37. Moreover, GV, 
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GIIA, and GIID sPLA2 bind the heparan sulfate proteoglycan, glypican, and this binding 
is required for AA release and PGE2 production5.  
1.1.4 GX sPLA2 
Within the sPLA2 family, GX sPLA2 has the most potent hydrolytic activity 
toward PtdCho, leading to the production of free fatty acids and LysoPtdCho (Figure 
1.2)38. GX sPLA2 has a wide tissue distribution39, which is reflected in the diversity of 
physiological processes GX sPLA2 is suggested to modulate. To this effect, a role for GX 
sPLA2 in the regulation of inflammation, lipoprotein metabolism, myocardial infarction, 
and innate immunity have all been described29,35,40-43. 
A role for eicosanoids as mediators of inflammatory processes including 
atherosclerosis is now well established (reviewed in44). GX sPLA2 appears to 
preferentially hydrolyze arachidonate and linoleate at the sn-2 position of PtdCho 
containing plasma lipoproteins45,46.  Indeed, the preference of GX sPLA2 for AA has 
important consequences with respect to eicosanoid generation. GX sPLA2 has been 
implicated in the production of eicosanoids including PGE2, PGD2, leukotriene B4, and 
cysteinylleukotrienes (cysLTs) in a Th2 cytokine-driven mouse model of asthma41. 
Importantly, both GX sPLA2 expression and cysLTs are increased in the airways of 
patients with asthma47. Our group has recently demonstrated a role for GX sPLA2 in the 
production of PGE2 in mouse pancreatic islet cells resulting in decreased glucose-
stimulated insulin secretion (Shridas et al., unpublished data).   
The pathophysiology of several disease processes stems from aberrant 
inflammatory responses in which GX sPLA2 has been shown to be involved. GX sPLA2 
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deficiency (GX KO) partially protects mice from myocardial ischemia/reperfusion injury, 
at least partly through the reduction of neutrophil cytotoxic responses42. Similarly, in a 
model of abdominal aortic aneurism (AAA) formation induced by CaCl2 application to 
the external surface of the aorta, GX KO mice are partially protected from AAA 
formation, likely through reduced production of neutrophil derived matrix 
metalloproteinase (MMP-9), elastase, and gelatinase48. Results from our lab have 
demonstrated a role for GX sPLA2 in promoting AAA formation in response to chronic 
subcutaneous infusion of angiotensin II (Ang II)49. Furthermore, gene expression analysis 
revealed that the mRNA levels of several inflammatory cytokines including 
cyclooxygenase-2 (COX-2), interleukin-6 (IL-6), matrix metalloproteinase-2 (MMP-2), 
MMP-13 and MMP-14 are significantly decreased GX sPLA2-/-/apoE-/- (GX DKO) mice 
compared to apoE-/- control mice. Additionally, GX KO mice show a marked reduction in 
allergen-induced interstitial edema and infiltration of inflammatory cells into the 
bronchoalveolar fluid and lung tissue41. Previous studies from our lab demonstrated GX 
KO mice have reduced plasma inflammatory cytokine expression in response to LPS 
injection, likely attributable to decreased toll like receptor 4 (TLR4) signaling in 
macrophages43. 
The lipolytic activity of GX sPLA2 may increase the atherogenicity of 
lipoproteins. GX sPLA2 expression is increased in atherosclerotic lesions35. To this effect, 
GX sPLA2 hydrolytic modification of LDL has been shown to result in increased 
cholesterol ester uptake by macrophages35. LDL phospholipid hydrolysis also led to 
increased levels of LysoPtdCho, which may contribute to the production of inflammatory 
cytokines50. Furthermore, in vitro studies in human umbilical cord endothelial cells 
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(HUVECs) suggest that GX sPLA2 modified LDL may increase adhesion molecule 
expression resulting in increased monocyte adhesion40. GX sPLA2 can also hydrolyze 
PtdCho in high density lipoproteins (HDL). The lipolytic modification of HDL by GX 
sPLA2 leads to decreased cholesterol efflux capacity from lipid loaded macrophages51. 
However, it should also be noted that when irradiated LDL-R deficient mice were 
reconstituted with bone marrow from GX sPLA2 deficient mice it had a proatherogenic 
effect, possibly due to enhanced plaque infiltration if T lymphocytes52. Hence, a complete 
understanding of the role of GX sPLA2 in the atherogenesis will likely only come from 
studies involving its tissue specific deletion. 
 Recent studies from our lab have defined a role GX sPLA2 as a negative regulator 
of liver X receptor (LXR) transcriptional activation. Accordingly, in vitro studies have 
demonstrated that exogenous addition recombinant GX sPLA2 or transgenic 
overexpression results in the suppression of LXR transcriptional activity and decreased 
target gene expression (Figure 1.3A). Conversely, in GX KO mice, LXR target gene 
expression is enhanced when compared to WT mice (Figure 1.3B). GX KO mice have 
enhanced LXR target gene expression peritoneal macrophages isolated from GX KO 
mice had increased expression of ATP-binding cassette transporter A1 (ABCA1) and G1 
(ABCG1), leading to enhanced cholesterol efflux capacity in these cells (Figure 1.4)53. 
Conversely, GX sPLA2 overexpression in J774 macrophages resulted in increased plasma 
membrane free cholesterol and lipid raft content43. The altered lipid raft content in GX 
sPLA2 overexpressing macrophages was associated with enhanced TLR4 signaling and 
an augmented inflammatory response to LPS43. Evidence from GX KO mice has also 
implicated GX sPLA2 in the regulation of adipogenesis54. When compared to control 
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mice, GX KO mice had increased age-related weight gain (Figure 1.5A, B) attributed to 
an increase in overall adiposity. Stromal vascular fraction (SVF) cells were isolated from 
GX KO mice and differentiated into adipocytes ex vivo, they accumulated significantly 
more triglyceride compared to SVF derived adipocytes from wild type mice. Conversely, 
GX sPLA2 overexpression resulted in decreased triglyceride accumulation in 
differentiated OP9 cells. Most notably, OP9 cells overexpressing GX sPLA2 had 
decreased expression of several LXR target genes involved in lipogenesis including 
SREBP-1c, FAS, SCD-1, and DGAT-1. We recently reported a role for GX sPLA2 in the 
adrenals where it modulates glucocorticoid (GC) production55. 
 GX KO mice have increased plasma corticosterone levels under both basal and 
adrenocorticotropic hormone (ACTH)-induces stress conditions (Figure 1.6). Mouse 
adrenals stained positive for GX sPLA2 in the zona reticularis and the zona fasciculata 
but not the zona glomerulosa regions of the adrenal cortex, consistent with GX sPLA2s 
ability to modulate GC but not mineral corticoid production. Experiments in GX KO 
mice using dexamethasone ruled out a systemic effect of GX sPLA2 on the hypothalamic-
pituitary axis. Primary adrenals from GX KO mice demonstrated a trend toward 
enhanced corticosterone production under basal conditions when compared to adrenal 
cells from control mice; this trend became highly significant upon stimulation with 
ACTH. The rate-limiting protein involved in adrenal GC production is steroidogenic 
acute regulatory protein (StAR). StAR expression was enhanced in the adrenals of GX 
KO mice under basal and ACTH-stimulated conditions. Conversely, StAR expression is 
suppressed in GX sPLA2 overexpressing Y1 (Y1-GX) cells. Importantly, Cummins et al. 
identified StAR as a bona fide LXR target gene56. StAR promoter activation in response 
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to the LXR agonist T0901317 was diminished in Y1-GX cells compared to control 
transfected (Y1-C) cells. Furthermore, Y1-GX cells had decreased progesterone levels 
compared to Y1-C cells under both basal and ACTH-stimulated conditions. Notably, GX 
sPLA2 dependent suppression of progesterone production was dependent on its hydrolytic 
activity. Indeed, GX sPLA2, but not thecatalytically inactive mutant H46Q, was able to 
inhibit progesterone production in Y1 cells. However, the regulatory mechanisms 
underlying GX sPLA2 activation in the adrenals have yet to be investigated. 
Given the potency with which GX sPLA2 hydrolyzes PtdCho, its enzymatic 
activity must be tightly regulated. Recent evidence suggests that GX sPLA2 may be 
transcriptionally regulated in response to certain inflammatory stimuli. Primary epithelial 
cells cultured in the presence of TNF-α/IL-1β, IL-13, and to a lesser extent IL-17 had 
enhanced GX sPLA2 expression when compared to untreated cells57. Conversely, IL-4 
and IL-25 decreased GX sPLA2 expression. However, results from our own lab suggest 
that GX sPLA2 mRNA is not increased in response to lipolysaccharide (LPS) in 
macrophages (Shridas et al., unpublished data).  The sPLA2 receptor (sPLA2-R) has been 
implicated in GX sPLA2degradation. In sPLA2-R expressing Chinese hamster ovary 
(CHO) cells, GX sPLA2 was rapidly internalized and degraded, and this was associated 
with diminished PGE2 production when compared to control CHO cells not expressing 
the sPLA2-R36. Moreover, a soluble form of sPLA2-R was found to bind and inactivate 
GX sPLA2. Indeed, in vitro incubation of GX sPLA2 with plasma from WT mice but not 
sPLA2-R deficient mice resulted in decreased phospholipase activity37.  
 GX sPLA2 is produced as an inactive proenzyme (pro-GX sPLA2), and propeptide 
cleavage appears to be necessary for enzymatic activity45. In GX sPLA2 transgenic mice, 
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the predominant form of the enzyme found in tissues is the inactive proenzyme58. It is 
only after the induced formation of inflammatory granulation tissue that proteolytic 
activation of pro-GX sPLA2 was observed. Within the 11 amino acid propeptide there is a 
dibasic motif, suggesting cleavage by furin-like proproteinconvertases (PCs)45 (Figure 
1.7). Indeed, use of the broad specificity peptide inhibitor, dec-RVKR-cmk, in GX sPLA2 
expressing HEK293 cells resulted in diminished pro-GX sPLA2 processing and 
phospholipase activity59. Furthermore, using both permeable and non-permeable PC 
inhibitors, it has been suggested that pro-GX sPLA2 processing and AA release occurs 
intracellularly. However, the sub-cellular location of pro-GX sPLA2 processing may vary 
between tissues. To this effect, while pro-GX sPLA2 processing and AA release may take 
place extracellularly in HEK 293 cells, AA release from CHO cells occurred both before 
and after enzyme secretion60. While PCs appear to be necessary for pro-GX sPLA2 
processing, at least in HEK 293 cells expressing a GX sPLA2 transgene, the identity of 
the individual PCs involved in a physiologically relevant system remains to be 
investigated.   
1.2 Furin-like proprotein convertases 
1.2.1 Mechanism of action and substrate specificity 
The subtilisin/kexin like proprotein convertase family consists of at least nine 
members, of which there are a core of seven biochemically and structurally related 
enzymes, namely PCSK1, PCSK2, furin, PCSK4, PCSK6, and PCSK761. The furin-like 
proprotein convertases (PCs) proteolytically activate zymogen targets through the 
recognition of dibasic motifs found within the substrates proregion. PCs are a group of 
calcium dependent serine-proteases that are themselves synthesized as proenzymes62. 
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Among the PCs, furin is the most extensively studied. In the case of furin, the propeptide 
is necessary for proper folding, and elimination or substitution of the native proregion 
resulted in an inactive enzyme63. This N-terminally located propeptide act as an 
“intramolecular chaperone” (IMC) and is autoproteolytically cleaved at -Arg-Thr-
LysArg107↓- in the endoplasmic reticulum64. The non-covalently linked but tightly 
bound IMC has been shown to act as an autoinhibitory peptide until a second 
autoproteolytic cleavage event leads to its disassociation63. The sequential, 
autoproteolytic cleavage of the IMC appears to take place in the endoplasmic reticulum 
and then in the trans-Golgi network (TGN). However, there is also evidence to suggest 
select PCs, most notably PCSK5A, and perhaps PCSK6, may retain their propeptide at 
the cell surface thus providing a mechanism for zymogen activation. In fact, in Y1 
adrenal cells, PC5A (PCSK5A) was retained at the cell surface complexed to its 
prosegment, and upon stimulation with ACTH, detection of the prosegment was 
decreased and only the active PCSK5A enzyme remained65.  
A clustering of negatively charged residues within the catalytic domain of these 
enzymes may account for their substrate specificity for dibasic motifs66,67. Proteolysis of 
substrates usually occurs at the recognition motif -Arg-X-Lys/Arg-Arg↓-, including a P1 
and P4 arginine68. The catalytic domains of furin-like PCs are remarkably well 
conserved, providing redundancy in substrate cleavage preferences. Therefore, the 
differential regulation of PC substrate recognition is likely determined, at least in part, by 
the various other regulatory domains governing PC-protein interactions, sub-cellular 
localization and trafficking, and Ca2+ and pH requirements. There is evidence that signal 
sequences within the cytoplasmic domain of PCs including furin, PCSK5B and PCSK7 
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are involved in their intracellular trafficking within the TGN61. PCSK5A and PCSK6 
interact with tissue inhibitors of metalloproteases (TIMPs) and heparin sulfate 
proteoglycans (HSPGs) through interactions with their cysteine-rich domains (CRDs)69. 
Downstream of the catalytic domain, the P domain is involved in modulating PC Ca2+ 
dependence and pH requirements61. 
1.2.2 Physiological functions 
The involvement of furin-like PCs in both maintaining homeostatic balance and in 
disease pathophysiology in humans has been the subject of intense investigation. 
Undoubtedly, the functional redundancy in substrate specificity seen among PCs 
confounds our understanding of their physiological function in vivo. Nonetheless, an 
emerging role for PCs in cancer, Alzheimer’s, infectious diseases, hyperlipidemia, and  
neuroendocrinopathies have all been described (reviewed in 61).  
Deficiency in PCSK1 and 2 in mice leads to severe neuroendocrinopathies 
resulting from inadequacies in prohormone processing. Deletion of PCSK1 has been 
linked to diminished processing of precursor hormones including growth hormone-
releasing hormone (GHRH), proopiomelanocortin (POMC), proinsulin, and proglucagon, 
leading to dwarfism70. Interestingly, a mutation in PCSK1 was identified in mice that 
resulted in an obese phenotype accompanied by marked hyperproinsulinemia in the 
absence of glucose intolerance71, perhaps reflecting alterations in substrate specificity61. 
Indeed, the obese phenotype of this mouse may be more representative of human PCSK1 
deficiency72. Similarly, PCSK2 deficiency results in glucoregulatory imbalances due to 
impaired processing of proglucagon, proinsulin, and prosomatostatin in pancreatic islet 
cells73.  Recently, using a panel of non-specific protease inhibitors, Jemel et al. 
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demonstrated a role for PCs in the proteolytic activation of ectopically expressed pro-GX 
sPLA2 in HEK 293 cells59. We have recently described a role for GX sPLA2 in regulating 
GC production in the adrenals55. However the role of PCs in regulating pro-GX sPLA2 
dependent modulation of glucocorticoid production has not been explored. 
1.3 Glucocorticoid physiology 
1.3.1 Regulation of adrenal glucocorticoid production 
The hypothalamic-pituitary-adrenal (HPA) axis controls the secretion of GCs by 
the adrenals through a tightly controlled negative feedback system. In the hypothalamus, 
corticotrophin releasing hormone (CRH) is released in response to stress. In response to 
CRH, the pituitary releases pro-opiomelanocortin (POMC), the precursor to ACTH. The 
release of ACTH by the pituitary then triggers GC production in the adrenal cortex, 
which in turn limits the stress response through a feedback loop that involves negatively 
regulating both CRH and POMC secretion from the hypothalamus and the pituitary 
respectively.   
Within the zona fasciculata of the adrenal cortex, ACTH stimulation of G-protein 
coupled receptors results in cyclic-AMP (cAMP)/protein kinase A (PKA) dependent 
mobilization of cholesterol to the inner mitochondrial membrane (IMM) where 
cytochrome P450scc (CYP11A1) metabolizes cholesterol to form pregnenolone, the 
precursor to all other steroid hormones. Interestingly, GC production is regulated, not at 
the level of CYP11A1 enzymatic activity, but by modulating the amount of cholesterol 
delivered to the mitochondria. In the adrenals, ACTH increases the expression of the 
sterol regulatory binding protein-1 (SR-B1) while also enhancing the expression and 
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activation of hormone sensitive lipase (HSL) which cumulatively leads to increased 
cholesterol trafficking to the mitochondria. The increased SR-B1 expression in the 
adrenals in response to ACTH provides substrates for steroid hormone synthesis through 
the “selective uptake” of HDL cholesterol74. Coordinately, ACTH also promotes the 
direct interaction between HSL and the cholesterol binding protein StAR, resulting in 
increased HSL mediated cholesterol ester hydrolysis from lipid droplets75. 
1.3.2 Steroidogenic acute regulatory protein  
The trafficking of cholesterol from the outer mitochondrial membrane (OMM) to 
the IMM in response to ACTH is mediated by StAR76,77. Mice deficient in StAR die 
shortly after birth due to adrenocortical insufficiencies78. The loss of negative-feedback 
regulation of the hypothalamic-pituitary-axis leads to the trophic hormone induced 
deposition of lipid in the adrenals of these mice, ultimately resulting in their death. The 
trophic hormone stimulation of StAR activity involves the rapid cAMP/PKA dependent 
phosphorylation of the 37-kDa precursor (p37), leading to its intramitochondrial 
processing and subsequent targeting of the mature phosphorylated form (pp30) to the 
inner mitochondria79. While StAR processing and activation is dependent on the 
synthesis of new StAR protein, it appears to precede increases in StAR gene expression. 
The transcriptional regulation of StAR in response to ACTH is facilitated by the PKA 
dependent activation of nuclear Janus kinase-signal transducer and activator of 
transcription (JAK/STAT), leading to the increased protein stability of the carbohydrate 
response element binding protein (CREB) and the transcription of steroidogenic genes 
including StAR80. Notably, a role for LXR in regulating adrenal cholesterol homeostasis 
has also been demonstrated56. In mice, LXRα/β deficiency leads to decreased ABCA1 
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expression and a derepression of StAR, resulting in a net decrease in cholesterol efflux 
and enhanced GC production. Most importantly, our lab has shown that adrenals 
harvested from GX KO mice have enhanced StAR gene expression under both basal and 
ACTH-induced stress conditions55. Furthermore, the enhanced StAR expression is 
associated with significantly increased plasma corticosterone levels. 
1.3.3 Role of arachidonic acid in regulating glucocorticoid production 
Importantly, several studies have now demonstrated a role for AA mediated 
steroid production in response to trophic hormone stimulation. PLA2s have been 
implicated in the generation of AA in human chorionic gonadotropin (hCG)-
stimulated Leydig cells81. Furthermore, the mitochondrial acyl-CoA thioesterase (MTE-I) 
mediates AA release from arachidonyl-coA in adrenal cortex cells and results in 
augmented steroid production82. It has also been demonstrated that knockdown of either 
MTE-1 or acyl-CoA synthetase (ACS4) by small interfering RNA leads to a marked 
reduction in cAMP stimulated steroidogenesis, probably by decreasing StAR 
expression83. The release of AA provides substrate for AA metabolizing enzymes 
including the cyclooxygenases (COX), lipoxygenases, and the cytochrome p450 
endoperoxidases. Notably, treatment of MA-10 Leydig cells with NS398, a COX2 
inhibitor, results in increased cAMP stimulated StAR expression and steroidogenesis84. 
Similarly, prostaglandin F2α has been shown to negatively regulateStAR expression 
through the AP-1 family member c-Fos85. Conversely, AA metabolites derived from 15-
lipoxygenase together with cAMP, synergistically activated steroidogenesis in adrenal 
cells86. However, studies from our own lab suggest that hydrolytic products generated in 
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response to GX sPLA2 overexpression in Y1 adrenal cells (i.e. AA) inhibits StAR 
expression through the suppression of LXR transcriptional activation55. 
1.3.4 Metabolic effects of glucocorticoids 
There is now evidence to suggest that hyperglucocorticoidism may contribute to 
the pathophysiology of the metabolic syndrome. Indeed, increased secretion of GCs in 
patients suffering from Cushing’s syndrome leads to central obesity, hyperglycemia, 
hyperlipidemia, glucose intolerance, and hypertension87. 
In the liver, GC administration leads to a marked increase in enzymes involved in 
fatty acid synthesis, including acetyl-CoA carboxylase88. In vitro stimulation of rat 
hepatocytes with GCs results to increased hepatic secretion of ApoB containing 
lipoproteins by enhancing protein synthesis of ApoB100 and ApoB48 while preventing 
the intracellular degradation of newly synthesized ApoB89. These findings are consistent 
with the idea that GC therapy induces lipid accumulation in the liver90,91 and may thus 
contribute to hepatic insulin resistance92. GCs also stimulate hepatic gluconeogenesis via 
interaction with the GC receptor and subsequently increasing expression of 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), the 
consequences of which result in enhanced hepatic glucose output and hyperglycemia93,94. 
Interestingly, adrenalectomy in ob/ob mice reverses the obese phenotype and GC 
replacement leads to reestablishment of obesity in adrenolectomized mice95. GCs may 
also impair insulin-dependent glucose uptake in adipocytes though a mechanism that 
involves decreased translocation of glucose transporter type-4 (GLUT4) to the plasma 
membrane96. Quite strikingly, GX KO mice have improved age-related glucose 
17 
 
intolerance, even in the face of increased adrenal GC production (Shridas et al., 
unpublished data).   
1.4 Metabolic syndrome and type-2 diabetes  
While the definition of the metabolic syndrome is somewhat a matter of debate, it 
is generally well agreed upon that it is associated with increased central adiposity, 
dislipidemia, elevated fasting blood glucose, and increased blood pressure. The metabolic 
perturbations associated with DIO are multifaceted and likely stem from a state of 
chronic low-grade inflammation, ultimately resulting in glucose intolerance and insulin 
resistance. The multi-organ pathogenesis leading to the metabolic dysregulation linked to 
type-2 diabetes (T2D) results from a failure to adequately respond to insulin.  
1.4.1 Role of macrophage inflammation in DIO 
The rapid expansion of adipose tissue (AT) in response to DIO is associated with 
AT remodeling and increased FFA flux which may contribute to insulin resistance and 
ectopic lipid deposition. The excessive accumulation of lipid into AT results in adipocyte 
hypertrophy and adipocyte cell death, which may lead to the infiltration of adipose tissue 
macrophages (ATMs)97. Monocyte chemoattractant proteins (MCPs) and their receptors 
play an integral role in recruiting immune cells to the sites of inflammation. Both 
genetically obese db/db mice and high fat diet (HFD) induced obese mice had increased 
AT expression of C-C motif chemokine ligand-2 (CCL2 or MCP-1)98. Furthermore, mice 
expressing an MCP-1 transgene under the control of the AP2 promoter show evidence of 
increased AT inflammation, diminished insulin sensitivity, and worsening hepatic 
steatosis98. There is evidence from genetically engineered mouse models to suggest that 
ATM recruitment to dysfunctional AT plays a causal role in the development of AT 
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inflammation and subsequently glucose intolerance and insulin resistance98,99. 
Macrophage dependent AT inflammation is mediated, at least in part by TLR4. TLR4 
deficiency in mice attenuates AT inflammation and insulin resistance in response to 
HFD, in the absence of reduced ATM infiltration100. The absence of TLR4 in bone 
marrow derived cells protects mice from HFD induced hepatic and AT insulin 
resistance101.  Lipid rafts/caveolae are thought to be essential components necessary for 
TLR4-dependent signal transduction102. Notably, macrophage ABCA1 reduced TLR4 
trafficking to lipid rafts by altering lipid raft cholesterol content103. We have recently 
shown that GX sPLA2 potentiates TLR4 dependent cytokine production in J774 
macrophages43. We attributed the enhanced inflammatory response to perturbations in 
cholesterol efflux capacity due to blunted ABCA1 expression. Recent evidence suggests 
that TLR4 deficiency may also result in an alternatively activated phenotype in 
macrophages leading to a blunted inflammatory response104. 
 The AT of lean mice is predominantly occupied by a less inflammatory 
“alternatively activated” M2 macrophage, characterized by the enhanced gene expression 
of Ym-1, arginase-1 and IL-10105. Whereas “classically activated” macrophages, 
secreting high levels of TNFα and iNOS, typify AT from diet induced obese mice. There 
is now evidence to suggest that this shift in macrophage polarity toward a pro-
inflammatory M1 phenotype may be causally linked to the development of glucose 
intolerance and insulin resistance associated with DIO. Indeed, the macrophage-specific 
deletion of peroxisome proliferator activated receptor-γ (PPARγ) impairs alternative 
activation and resulted in enhanced AT inflammation, glucose intolerance, and insulin 
resistance106. The agonist activation of LXR has been shown to increase PPARγ gene 
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expression107. Moreover, bone marrow-derived macrophages from WT mice are more 
reminiscent of alternatively activated macrophages, secreting more IL-10 and less 
proinflammatory cytokines, than macrophages isolated from ABCA1 deficient mice108. 
Peritoneal macrophages isolated from GX KO mice have enhanced LXR target gene 
expression, including ABCA1 and ABCG153. However, the role of GX sPLA2 in 
promoting macrophage mediated inflammation in a model of DIO has not been 
investigated. 
1.4.2 AT dysfunction in DIO 
 It has been suggested that it is not the expansion of AT per se but the 
dysfunctional expansion of AT that may lead to ATM recruitment and metabolic 
dysfunction. Indeed, large hypertrophic adipocytes have been associated with genetic or 
DIO are linked to ectopic lipid deposition, insulin resistance and glucose intolerance109. 
Alternatively, when AT expansion results in adipocyte hyperplasia, stemming from the 
recruitment and differentiation preadipocytes, a “metabolically healthy but obese” 
(MHO) phenotype, lacking the metabolic dysregulation associated with over-nutrition, 
prevails110. Thus, tipping the scale toward a more hyperplastic AT phenotype tends to 
lend itself to an improved metabolic profile. To this effect, in the face of massive 
subqutaneous AT expansion, adiponectin transgenic ob/ob (Ad Tgob/ob) mice have 
smaller adipocytes and improved insulin sensitivity and glucose tolerance compared to 
control ob/ob mice111. Ad Tgob/ob mice have increased expression PPARγ, the master 
regulator of preadipocyte differentiation, in the AT compared to control mice. Notably, 
administration of PPARγ agonists, thiazolidinediones (TZDs), has also been shown to 
result in healthy AT expansion resulting in smaller adipocytes and improved insulin 
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sensitivity112. LXR response elements have been identified in the promoter region of 
PPARγ107. The LXR agonist, T0901317, has been shown to promote adipocyte 
differentiation, demonstrating marked increases in PPARγ and several genes involved in 
lipid metabolism107. Furthermore, agonist activation of LXR improves glucose tolerance 
in a model of DIO113. Upon differentiation, stromal vascular fraction (SVF) cells isolated 
from GX KO mice have increased lipid accumulation compared to SVF from WT mice54. 
On the other hand, GX sPLA2 overexpression in differentiated OP9 cells results in 
diminished lipogenic gene expression compared to control cells. Intriguingly, GX KO 
mice demonstrate increased age-related weight gain compared to WT control mice. This 
increased weight gain is due to increased adiposity and hypertrophic adipocytes. 
Paradoxically, GX KO mice are protected from age-related glucose intolerance compared 
to WT control mice. However, the role of GX sPLA2 in promoting metabolic dysfunction 
in a model of DIO has not been explored. 
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Table 1.1: Phenotype of sPLA2 gene-manipulated mice. 
(Adapted from Murakami et al., Biochimie, 2013) 
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Figure 1.1: The sPLA2 family.  
(Adapted from Murakami et al., J. Biochem, 2011) 
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Figure 1.2: GX sPLA2 hydrolyzes phosphatidylcholine at the sn-2. 
GX sPla2 cleaves the sn-2 ester bond of phosphatidylcholine (PtdCho) producing free 
fatty acids (FFAs), most notably arachidonic acid (AA), and 
lysophsophosphatidylcholine (LysoPtdCho).  
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Figure 1.3: GX sPLA2 negatively regulates LXR transcriptional activity. 
A. GX KO mice have enhanced liver X receptor (LXR) target gene expression, resulting 
in a mouse with hypercorticosteronemia, increased adiposity, and a blunted inflammatory 
response. B. GX sPLA2 overexpression results in blunted LXR target gene expression 
resulting in suppressed glucocorticoid production by adrenal cells, decreased triglyceride 
accumulation in adipocytes, and enhanced macrophage inflammatory responses. 
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Figure 1.3: (continued) 
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Figure 1.4: Relative expression of ABCA1 and ABCG1 mRNAs in MPMs from WT 
and GX KO mice.  
Data are relative to WT MPM values; **P < 0.01 compared to WT MPMs. (Adapted 
from Shridas et al., JBC, 2010). 
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Figure 1.5: GX KO mice have increased age-related weight gain compared to WT 
mice. 
A. Male C57BL/6 and GX KO mice in a C57BL/6 background were fed a normal rodent 
diet for 12 mo. B. Male C57BL/6 and GXKO littermates were singly housed at weaning, 
and body weights were determined weekly (n=4).*P<0.05 (Adapted from Li et al., 
FASEB J, 2010). 
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Figure 1.6: GX KO mice have hypercorticosteronemia.  
Blood was collected from anesthetized 9-month-old WT (n = 5) and GX KO (n = 7) 
female mice by cardiac puncture. For ACTH treatments, 10-week-old mice received 
subcutaneous injections of 0.1 ml of saline or saline containing 4 units of ACTH at times 
0, 12, and 24 h (n = 6).**P<0.01, ***P<0.01(adapted from Shridas et al., JBC, 2010). 
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Figure 1.7: GX sPLA2 is cleaved by furin-like proprotein convertases. 
A. Schematic representation of GX sPLA2. GX sPLA2 is produced as a zymogen (pro-
GX sPLA2). B. The cleavage site within the prosegment contains a highly conserved 
dibasic motif, suggesting cleavage by furin-like proprotein convertases.  
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Figure 1.8: Structure of Decanoyl-RVKR-cholomethylketone.  
Peptidyl chloroalkylketones containing the R-X-K/R-R motif irreversibly bind to the 
catalytic site of furin-like proprotein convertases (PCs), thereby inhibiting substrate 
processing114.  
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Chapter Two 
Methods 
Mice 
Targeted deletion of GX sPLA2was carried out by InGenious Targeting 
Laboratory Inc. using embryonic stem cells derived from C57BL/6 mice. The targeting 
vector included a Neo cassette trapped inside exon 1, upstream of the translational start 
signal thereby replacing 564 bp of the GX sPLA2 gene (Figure 2.1). Heterozygous 
breeding strategies were employed to produce male age-matched GX+/+ (WT) and GX-/- 
(GX KO) mice. Mice were fed normal mouse chow diet ad libitum and were housed in an 
area on a 14-hour light/10-hour dark cycle. For some studies, 10-week old mice were 
assigned to either low fat diet (10% lard, D12450B, Research Diets) or high fat diet (60% 
lard, D12492, Research Diets) groups and maintained on diets for 16 weeks. 
Glucose Tolerance Tests 
Mice were fasted for six hours at which point they were weighed. Baseline 
glucose values were then determined using a Contour glucose meter and test strips (Bayer 
HealthCare LLC) via tail vein prick with an 18 gauge 1 ½ inch needle. Mice were then 
given injections of a solution of 20% d-+-glucose (Sigma G7021) prepared in sterile 
phosphate buffered saline (PBS) intraperitoneally at a dose of either 1.5 g glucose per kg 
of body weight (0 and 4 weeks on diet) (i.e., 10 µl per gram of body weight) or 2 g 
glucose per kg body weight (8, 12, and 16 weeks on diet). Blood glucose measurements 
were then recorded 30, 60, 90, 120, and 180 minutes after glucose injection. 
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Insulin Tolerance Tests 
Mice were fasted for six hours at which point were weighed. Baseline glucose 
values were then determined using the glucose meter via tail vein prick with an 18 gauge 
1 ½ inch needle. Mice were then injected with Novolin R recombinant human insulin, 
(Novo Nordisk A/S) at a dose of 1 unit per kilogram of body weight. Blood glucose 
measurements were then recorded 30, 60, 90, 120, and 180 minutes after insulin 
injection. 
RNA extraction from adipose tissue 
Adipose tissue was excised and snap-frozen in liquid nitrogen until further 
processing. For RNA extraction, the RNeasy Lipid Tissue Kit (Qiagen) was used. To 
begin, approximately 100 mgs of frozen tissue was immediately added to 1mL of 
Qiazollysis reagent and placed on ice (1mL eppendorf tube). Lysis of adipose tissue was 
achieved using a hand homogenizer (VWR) for 15-30 seconds per sample. After a minute 
incubation 200 μL of chloroform was added to each sample at which point samples were 
vortexed for 10 seconds each. Samples were then centrifuged at 16,100 x g for 10 
minutes at 4oC. Upon centrifugation, the upper, acqueous layer was transferred into a 
fresh 1 mL eppendorf tube containing 600 µL of 70% ethanol. After mixing by briefly 
vortexing, up to 700 µL of sample was transferred to an RNeasy spin column placed in a 
2mL collection tube. Sample was then centrifuged at 16,100 x g for 1 minute at 4oC. 
Flow-through was discarded and the process was repeated as necessary until the entire 
sample had been transferred to the spin column. Following centrifugation 700 µL per 
sample of buffer RW1 was added to the spin column and samples were again centrifuged 
at 16,100 x g for 1 minute at 4oC. The flow-through was discarded. 500 µL of buffer RPE 
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per sample was then added to the spin column and it was centrifuged at 16,100 x g for 1 
minute at 4oC.  After the flow through was discarded, the spin column containing the 
sample was centrifuged once more at 16,100 x g for 1 minute at 4oC to remove any 
residual wash buffer. Spin column was then placed in a clean 1mL eppendorf tube at 
which point 40 µL of RNase free water was added to each spin column in order to elute 
the RNA. RNA concentrations were quantified using the NanoDrop Spectrophotometer 
(Thermo Scientific) and stored at -80oC until further use. 
Immunofluorescent staining 
Adipose tissue was collected and fixed in 10% paraformaldehyde. 5 μM thick, 
paraffin embedded adipose tissue samples were mounted on glass slides. For 
deparaffinization, slides were immersed in xylene (3x for 5 minutes each), followed by 
immersion in progressively diluted ethanol solutions, 100% ethanol, 3x for 2 minutes 
each, 95% ethanol, 3x for 2 minutes each, and 70% ethanol, 3x for 2 minutes each, 
followed by a 2x rinse in PBS for 1 minute each. This was followed by a 30 minute heat-
induced antigen retrieval (HIER) in which samples were immersed in 1x (DAKO) 
antigen retrieval buffer and placed in boiling water bath for 30 minutes. Upon completion 
samples were allowed to cool for at least 1 hour. Samples were then washed in PBS and 
immersed in a hydrogen peroxide solution (800 μL 30% w/w H2O2 in 50 mL PBS) for 10 
minutes to quench endogenous peroxidases. The samples were then rinsed in PBS and 
incubated in TNB [180 mL ddH2O plus 20 mL of 10X TN buffer, (for 1L 10X TN buffer; 
121.14 g Tris-HCl free base, 87.7 g NaCl, 800 mL, pH to 7.5 with 6N HCl) plus 1 g of 
Perkin Elmer blocking reagent (cat. # FP1020), warmed to 60oC for 1 hour]. After 1 hour 
TNB was drained off and 250 μL of primary antibody diluted in TNB (1/100) was added 
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to samples. After overnight incubation in humidified container at 4oC, primary antibody 
was drained off and samples were washed TNT buffer (160 ml of 10x TN, 16 mL of 10% 
Triton-X, ddH2O to 1600 mL), 3x for 5 minutes each. The samples were then incubated 
in secondary antibody diluted in TNB (1/1000) (Peroxidase AffiniPureF(ab')2 Frag Goat 
Anti-Rat IgG, Jackson Laboratories 112-036-072) for 1 hour at room temperature. The 
secondary antibody was then drained off and sample was again washed in TNT buffer, 3x 
for 5 minutes each. A 1/50 dilution of TSA stock was prepared using amplification 
diluent from TSA, Plus Cyanine 3 System (Perkin Elmer). The samples were then 
incubated in TSA for 10 minutes at room temperature followed by a 3x wash cycle in 
TNT buffer (5 minutes each). After wash buffer was drained, mounting media was added, 
Anti-Fade Reagent containing DAPI (Invitrogen) and slide covers were added. The next 
day samples were analyzed using fluorescence microscopy. 
Phospholipase activity assay 
Conditioned media was harvested and assayed for phospholipase activity using a 
colorimetric assay as previously described by Wooton-Kee et al115. Briefly, using 1-
palmitoyl-2-oleoylphosphatidylglycerol (POPG) (Matreya) as substrate, mixed micelles 
were prepared by dissolving 7 mg of POPG in 0.2 mL mixture of 4.0% (w/v) Nonidet P-
40 and 2.0% sodium deoxycholate to 37oC, and then adding 1.8 ml of warm assay buffer 
(0.12 mol/liter Tris-HCl, pH 8, 12 mmol/liter CaCl2, 0.1 mmol/liter EDTA). Enzymatic 
activity was assayed by adding 10μl of conditioned media 40μl of substrate solution. 
After incubating at 37oC for 20 minutes, the amount of free fatty acids released was 
quantified using a NEFA-C kit (Wako Chemicals). 
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sPLA2 activity assay 
Media was collected and centrifuged at 16,100 x g for 5 minutes at 4oC. Upon 
centrifugation media was transferred into fresh 1 mL eppendorf tube. sPLA2 activity was 
measured using sPLA2 assay kit (Cayman Chemical) according to the manufacturers’ 
instructions. Briefly, 10 μL of clarified media was assayed for phospholipase activity 
using a 1, 2-dithio analog of diheptanoylphoosphatidylcholine. Upon hydrolysis of the 
thioester bond at the sn-2 position, free thiols were detected using 5, 5-dithio-bis-(2-
nitrobenzoic acid) (DTNB). The plate was immediately placed in an xMARKmicroplate 
reader spectrophotometer (Bio-Rad) and absorbance was measured at 414 nM every 
minute for 20 minutes. 
Immunobotting 
Cells were washed using Delbecco’s phosphate buffered saline (DPBS) and 
harvested using RIPA buffer (Sigma) supplemented with Complete Mini protease 
inhibitor cocktailtablets (Roche). Total cellular protein was quantifiedusingBicinchoninic 
acid (BCA) assay. For StAR protein expression analysis, 10μg of cell lysate was resolved 
by sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) (4% 
stacking/10% resolving gel) and transferred to a polyvinylidene fluoride (PVDF) 
membrane Immobilon-P (Millipore) for western blotting. Membranes were blocked in 
TBST (20mM Tris, 200mM NaCl, 0.5% Tween 20, pH 7.6) containing 5% nonfat mild 
for 1 hour. After blocking, membranes were washed with TBST followed by overnight 
incubation at 4oC using an anti-StAR primary antibody (Santa Cruz, StAR FL-285) 
diluted in TBST containing 5% nonfat milk. Membranes were again washed with TBST 
and incubatedin HRP-conjugated secondary antibody in TBST containing 5% nonfat milk 
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for 2 hours at room temperature. Following a final wash in TBST, membranes were 
incubated for 2 minutes in enhanced chemiluminescence (ECL) (Amersham) and 
analyzed using autoradiography film.  Quantification of bands was carried out using 
Image Station 440 (Kodak) and the Kodak ID 3.6 software. For GX sPLA2 protein 
expression analysis, conditioned media was centrifuged at 16,100 x g for 5 minutes at 
room temperature and transferred to a fresh 1mL eppendorf tube. 20μL of conditioned 
media was resolved by SDS-PAGE (4% stacking/14% resolving gel) and processed as 
described above using an anti-FLAG antibody (Agilent, anti-FLAG M2). 
Reporter Assays 
Y1 BS1 adrenal cells were grown to approximately 75% confluence and then 
transfected with mouse 3X-FLAG-tagged GX sPLA2 expression vector or the 
corresponding pcDNA3.0 control vector (0.4μg) along with pTK-3-LXRE-Luc reporter 
construct (0.4μg), mLXRα, (0.1μg), mRXR (0.1μg), renilla- luciferase (Promega, 
0.02μg), and furin or PCSK6 (0.4μg) (Origene) using Lipofectamine 2000 according to 
the manufacturer’s protocol. Both the mLXR and the 3X-LXRE were gifts from Dr. Peter 
Tontonoz (UCLA). After 18 hours, cells were incubated in fresh media (high glucose 
DMEM (HyClone), supplemented with 10% heat-inactivated fetal bovine serum, 100 
units/ml penicillin, and 100 μg/ml streptomycin), and either 0 or 1μM T0901317 for 24 
hours. Cells were washed with DPBS and harvested in 1 x PLB buffer (Promega). 
Luminescence was measured using the Dual-Luciferase Reporter Assay System 
(Promega). 
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Quantitative real time-PCR 
Cells were grown in 24-well plates and total RNA was harvested using RNeasy 
Mini Kit (Qiagen) according to manufacturers’ instructions. Briefly, cells were harvested 
in 350 µL RLT buffer containing 10 µL Beta-mercaptoethanol/mL of RLT. Sample was 
immediately added to 350 µL 70% ethanol and vortexed. Sample was transferred to 
RNeasy spin column and centrifuged at 16,100 x g for 1 minute at 4oC. The flowthrough 
was discarded and 750 µL RW1 buffer was added to spin column followed by 
centrifuged at 16,100 x g for 1 minute at 4oC. Flowthrough was again discarded and 500 
µL of RPE buffer was added followed by centrifugation at 16,100 x g for 1 minute at 
4oC. This step was repeated a second time. Samples were then centrifuged at 16,100 x g 
for 2 minutes at 4oC to remove any residual liquid. The spin column was transferred to a 
clean 1 mL eppendorf tube at which point 30 µL of RNase free H2O was added to spin 
column and samples were incubated at room temperature for 1 minute followed by 
16,100 x g for 1 minute at 4oC. RNA abundance was quantified using the NanoDrop 
Spectrophotometer (Thermo Scientific) and stored at -80oC until further use. Reverse 
transcription was carried out using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Quantitative real time-PCR was carried out using Power SYBR 
Green PCRMaster Mix (Applied Biosystems) using the following restrictions: 95oC for 3 
minutes; 95oC for 10 seconds, 58o for 30 seconds, 72oC for 30 seconds (40 cycles); 10oC 
hold.  Primer sequences specific for particular genes of interest are presented in Table 
2.1. 
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Gene silencing with small interfering RNA (siRNA) 
A set of ON-TARGET plus SMART pool siRNA (Thermo Scientific) synthetic 
oligonucleotides  directed toward the mouse PCSK6 target sequences (5’-
UAAACAAGCUUUCGAGUAU-3’, 5’-GGUCAGAGAUGAACGUCCA-3’, 5’-
CGAGAUGCCUGGCGUCACA-3’, and 5’-GAUGAGACCUUCUGCGCGA-3’) and 
toward the mouse furin target sequences (5’-CGACAUCGGCAAACGGCUA-3’, 5’-
GAAGAAUCAUCCCGACCUA-3’, 5’-GAAAGUGAGCCAUUCGUAU-3’, and 5’-
GCGCCACACAGUUCGGCAA-3’). The ON-TARGET plus Non-targeting pool 
(Thermo Scientific) was used as a control. The transfection of GX sPLA2 3x-FLAG 
stably expressing Y1 adrenal cells (Y1-GX) was achieved using Dharmafect 1 
transfection reagent (Thermo Scientific) according to manufacturer’s instructions.  
Expression of GX sPLA2 in Y1 cells 
Murine Y1 adrenal cells were purchased from American Type Culture Collection 
(ATCC) and maintained in F-12K media (ATCC) supplemented with 2.5% non heat-
inactivated fetal bovine serum (Invitrogen), 15% non heat-inactivated horse serum 
(Invitrogen), 100 units/mL penicillin, 100 µg/mL streptomycin. A C-terminal 3x FLAG-
tagged mouse GX sPLA2cDNA was developed by PCR using forward (5’-
CTGAAGCTTATGCTGCTGCTACTG-3’) and reverse (5’-
ATGAATTCTCACTTGTCATCGTCGTCCTTGTAGTCGATATCGTGGTCCTTGTAG
TCTCCATCGTGGTCCTTGTAGTAGTCATT-3’) primers containing HindIII and 
EcoRI restriction sites, respectively, and a previously generated GX sPLA2 fused to a 
single C-terminal FLAG-tag in pcDNA 3.1 (Invitrogen) as a template55. The PCR product 
was purified over a 1% agarose gel in 1x Tris-acetate buffer (TAE) (for 1 L of 50x, 242 g 
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Tris base 57.1 mL glacial acetic acid, and 0.5 M EDTA, pH 8.0) containing 0.02% 
ethidium bromide. PCR product was eluted from gel using QIAguick Gel Extraction Kit 
(Qiagen). Then both the GX sPLA2cDNA and pcDNA 3.1 was incubated at room 
temperature for 4 hours with HindIII and EcorI endonucleases (New England Biolabs, 
NEB). The digestion product was again purified over a 1% agarose gel and purified using 
the Qiagen gel extraction kit. A ligation reaction was then carried out at room 
temperature for 10 minutes using T4 DNA ligase (NEB) and a molar ratio of GX 
sPLA2cDNA/pcDNA 3.1 of 3/1. The ligation reaction mixture was then used to transform 
5-alpha F’Iq competent e-coli cells (NEB) according to the manufacturer’s instructions. 
The DNA sequence was confirmed in collaboration with Davis Sequencing. Y1 cells 
were then transfected with the C-terminal 3x FLAG-tagged GX sPLA2 using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Stable 
clones were selected for using 500μg/mL G418 (Invitrogen). 
Co-expression of GX sPLA2 with furin and PCSK6 
Mouse cDNA clones for furin (accession # BC048234) and subtilisin/kexin type 6 
(PCSK6) (accession # NM_011048.1) were purchased from Origene (catalog # 
MC202300 and MR215393, respectively). HEK 293 cells were maintained in 
DMEM/High Glucose (HyClone) supplemented with 10% heat-inactivated FBS 
(Invitrogen) and 100 units/mL penicillin, 100 µg/mL streptomycin. All experiments were 
carried out in 24 well plates grown to ~80% confluency at the time of transfection. 0.8 μg 
DNA total was transiently transfected using Lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s protocol. Briefly, using a ratio of 1 μg DNA/2.5 μLLipofectamine, 0.8 
μg DNA/ well was diluted up to 50 μL with serum-free Opti-MEM (Invitrogen) and 
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incubated at room temperature for 5 minutes. At the same time 2 μL of 
Lipofectamine/well was diluted up to 50 μL with serum-free Opti-MEM and incubated a 
room temperature for 5 minutes. After 5 minute incubation period, 50 μL of diluted 
Lipofectamine was added to 50 μL of diluted DNA and incubated at room temperature 
for 20 minutes to allow DNA-Lipofectamine complexes to form. After the 20 minute 
incubation period, 100 μL of DNA-Lipofectamine complexes was added to each well. 
HEK 293 cells were then incubated for 8 hours in transfection media. Cells were then 
incubated in fresh media for 24 hours. Upon harvest, cells were washed with 0.5 mL of 
ice-cold PBS. After aspirating off PBS, whole cell lysates were harvested in 100 μL 
RIPA lysis buffer (Sigma) and stored in -20oC. The media was collected and centrifuged 
at 16,100 x g for 5 minutes at 4oC. After centrifugation, media was transferred to a fresh 
1 mL eppendorf tube and stored at -20oC until further processing.  
Progesterone Assay 
Media was collected and centrifuged at 16,100 x g for 5 minutes at 4oC. Upon 
centrifugation media was transferred into fresh 1 mL eppendorf tube. Samples were 
stored at -80oC until further processing. Progesterone in the media was measured using 
the Progesterone EIA kit (Cayman Chemicals) according to the manufacturer’s 
instructions.  Briefly, media samples were diluted in EIA buffer 1/25. It is a competition 
based assay in which progesterone competes with progesterone conjugated to an 
acteylcholinesterase (AChE) (progesterone tracer) for binding. AChE cleaves 
acetylcholine, exposing the free thiol which is then free to react with the detection 
reagent DTNB.  
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Statistics 
 Statistical analysis between two groups was carried out using a two-tailed 
student’s t-test. For comparison of more than two groups, statistical significance was 
determined using a 1-way analysis of variance (ANOVA) followed by Tukey’s post-hoc 
analysis. For comparisons between multiple treatment groups, a 2-way ANOVA was 
used (example; diet and genotype). In the case of non-normally distributed data, a Mann-
Whitney test was performed to determine significance between groups. 
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Table 2.1: List of primers used for qRT-PCR analysis. 
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Figure 2.1: Generation of GX sPLA2 deficient mice.  
White boxes represent exons. Restriction enzyme sites are indicated. In this approach, the 
Neo cassette is trapped inside exon 1 before the ATG and replaces 564 bps of the gene 
Figure provided by InGenious Targeting Laboratory Inc. 
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Chapter Three 
GX sPLA2 deficiency does not protect mice against high fat diet induced metabolic 
dysfunction and adipose tissue inflammation 
3.1 Introduction 
Diet induced obesity is associated with metabolic derangements including glucose 
intolerance and insulin resistance116. The rapid expansion of adipose tissue (AT) in 
response to diet induced obesity (DIO) is associated with the recruitment of adipose 
tissue macrophages (ATMs). It is now well established that AT infiltration by ATMs 
leads to glucose intolerance and peripheral insulin resistance97. However, the sequence of 
events contributing to the recruitment of inflammatory ATMs remains unclear. 
It has been hypothesized by Cinti and colleagues that DIO leads to the acquisition 
of an AT phenotype characterized by necrotic-like adipocyte death117. In this model, the 
excessive accumulation of lipid into AT results in adipocyte hypertrophy and eventually, 
adipocyte cell death. The formation of crown-like structures (CLSs), sites of macrophage 
infiltration and inflammation, may then contribute to decreased insulin sensitivity. We 
have recently shown that when compared to wild type (WT) mice, GX sPLA2 deficient 
mice (GX KO) have increased age-related weight gain54. The increased weight gain in 
GX KO mice is associated with increased adiposity and enlarged adipocytes. When 
stromal vascular fraction (SVF) cells are isolated from both GX KO and WT mice and 
differentiated into mature adipocytes, SVF cells from GX KO mice accumulate 
significantly more triglycerides than SVF cells from WT mice. This phenotype likely 
results from the derepression of liver X receptor (LXR) transcriptional activation of 
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lipogenic gene expression. Paradoxically, this increased adiposity in GX KO mice is 
associated with improved age-related glucose intolerance (Shridas et al., unpublished 
data). Therefore, GX KO mice may provide a unique model for understanding 
mechanisms involved in the recruitment of ATMs to dysfunctional AT. 
The metabolic dysfunction associated with diet-induced obesity, including 
impaired glucose tolerance and decreased insulin sensitivity, may be attributed to 
macrophage derived AT inflammation118,119. Interestingly, when compared to control 
mice, GX KO mice have reduced plasma cytokine levels in response to i.p. injection of 
lipopolysaccharide (LPS)43. This phenotype is associated with blunted toll-like receptor 4 
(TLR4) signaling in macrophages, presumably due to altered macrophage lipid raft 
cholesterol content. Peritoneal macrophages isolated from GX KO mice have increased 
expression of the cholesterol efflux transporters ATP-binding cassette A1 (ABCA1) and 
G1 (ABCG1); well-established LXR target genes. Moreover, GX KO macrophages 
demonstrate enhanced ApoA1 mediated cholesterol efflux capacity compared to WT 
mice. Nevertheless, the role of GX sPLA2 in modulating HFD induced metabolic 
dysfunction and AT inflammation has yet to be investigated. Hence, we hypothesized that 
GX sPLA2 deficiency would protect against HFD induced AT inflammation and 
metabolic dysfunction. 
3.2 Results 
GX sPLA2 deficiency has no effect on HFD induced adiposity.  
We have previously reported that GX KO mice have increased age-related 
adiposity54. To determine if GX sPLA2 deficiency alters body composition in response to 
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HFD, DIO was established in both WT and GX KO mice (Figure 3.1A). However, after 
16 weeks of HFD feeding there was no apparent difference in the body weights or body 
composition between genotypes in either the low fat (LF) or high fat (HF) fed groups 
(Figure 3.1A, B). 
GX sPLA2 deficiency does not alter plasma lipid profiles in response to HFD.  
To determine if GX sPLA2 deficiency altered plasma lipid profiles of mice fed a 
HFD, we analyzed plasma total cholesterol, triglycerides, and free fatty acids. While 
plasma total cholesterol was significantly increased in both WT and GX KO mice fed a 
HFD, no significant difference between genotypes in either low fat or high fat fed groups 
was observed (Figure 3.2A). Furthermore, no differences in plasma triglycerides or 
plasma free fatty acids was observed in response to HFD in either genotype (Figure 3.2B, 
C). 
GX sPLA2 deficiency partially protects against HFD induced glucose intolerance but 
not insulin resistance.  
In order evaluate the effect of GX sPLA2 deficiency on the metabolic 
derangements associated with HFD feeding, glucose and insulin tolerance tests were 
performed at 4 week intervals. After 8 weeks of HFD feeding, WT but not GX KO mice 
demonstrated decreased glucose tolerance in response to i.p. glucose challenge as 
measured by the area under the curve (AUC) (Figure 3.3). Unexpectedly, after 12 weeks 
of HF feeding GX KO mice were no longer protected against HFD induced glucose 
intolerance when compared to WT mice, and this relationship held true through the 
remainder of the study (Figure 3.3). In order to evaluate alteration in insulin sensitivity in 
response to HFD feeding insulin tolerance tests were performed.  Insulin resistance in 
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response to HDF feeding was not apparent until 16 weeks of feeding as assessed by the 
AUC (Figure 3.4). However, there were no apparent differences in insulin sensitivity 
between genotypes in either the LF or HF fed groups. 
HFD-induced adipocyte hypertrophy is not altered by GX sPLA2 deficiency.  
The increase in fat mass in response to HFD (Figure 3.1A) was associated with 
enlarged adipocytes in both WT and GXKO mice (Figure 3.5A) and there were no 
apparent differences in adipocyte size between genotypes in either the LF or HF fed 
groups (Figure 3.5C). However, there did appear to be a trend toward larger adipocytes in 
GX KO mice fed a HFD (Figure 3.5B).  
GX sPLA2 deficiency does not protect against HFD-induced ATM infiltration of AT.  
The expansion of AT in response to HFD leads to active AT remodeling and is 
associated with a depot dependent infiltration of inflammatory ATMs97. Hence, the 
presence of F4/80, a pan macrophage marker, was quantified in epididymal adipose tissue 
(eAT) by immunofluorescent staining. When compared to LF fed mice, an increase in 
ATM infiltration was seen in both WT and GX KO mice fed a HFD, but there was no 
difference in the diet dependent accumulation of ATMs between genotypes after 16 
weeks of feeding (Figure 3.6B). Results from immunofluorescent staining were 
confirmed using qRT-PCR analysis (Figure 3.6A), clearly demonstrating a HFD 
dependent increase in F4/80 mRNA isolated from eAT in both WT and GX KO mice 
with no significant difference between genotypes.  
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GX sPLA2 deficiency does not protect against AT inflammation in response to HFD.  
The infiltration of ATMs in response to HFD is accompanied by the increased 
gene expression of inflammatory mediators which may play a causal role in the 
development of insulin resistance and type-2 diabetes118. Therefore, we analyzed 
expression levels of several of cytokines implicated in AT insulin resistance. When 
compared to LF fed mice, the expression levels several cytokines including tumor 
necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-1β 
(IL-1β), and monocyte chemoattractant protein-1 (MCP-1), were increased in eAT 
isolated from both WT and GX KO mice fed a HFD (Figure 3.7).Nonetheless, GX sPLA2 
deficiency was unable to abrogate the increases in inflammatory cytokine expression in 
response to HFD120.  
GX sPLA2 deficiency does not alter the polarization of infiltrating ATMs in 
response to HFD.  
The AT expansion associated with obesity results in a phenotypic switch in the 
polarization of ATMs toward a more inflammatory profile. ATM polarization appears to 
be an important determinant in the development of glucose intolerance and insulin 
resistance in response to HFD106,120,121. Hence, we looked to see if deficiency in GX 
sPLA2 altered the polarization of infiltrating ATMs. The M1 “classically activated” 
macrophages have increased gene expression of inflammatory mediators including TNF-
α and inducible-nitric oxide synthase (iNOS)120. TNF-α, but not iNOS, expression was 
increased in the eAT in both WT and GX KO mice in response to HFD (Figure 3.8A). 
Unexpectedly, TNF-α was significantly increased in GX KO mice when compared to WT 
mice fed a HFD. When mannose receptor (MR) and arginase-1 (markers of “alternatively 
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activated” M2 macrophages) gene expression were analyzed in the eAT, a HFD 
dependent increase in MR was observed with no significant differences between 
genotypes (Figure 3.8B). The expression of arginase-1 was only increased in GX KO 
mice fed a HFD but results were confounded by extreme variability. 
3.3 Discussion 
Type-2 diabetes is a chronic inflammatory disease characterized by the 
dysregulation of hepatic glucose metabolism, decreased glucose uptake in insulin-
sensitive tissue including skeletal muscle and AT, and pancreatic β-cell dysfunction. We 
recently reported that when compared to control mice, GX KO mice have increased age-
related weight gain due to an increase in adiposity54. However, the increased adiposity in 
the GX KO mice was associated with improved age-related glucose intolerance. 
Additionally, GX sPLA2 deficiency resulted in a marked improvement in pancreatic β-
cell function as assessed by glucose-stimulated insulin secretion (GSIS) (Shridas et al., 
unpublished data). Notably, GX KO mice had diminished plasma cytokine levels in a 
model of sepsis, likely the result of attenuated macrophage mediated inflammatory 
responses43. In the present study we investigated the role of GX sPLA2 in HFD induced 
metabolic dysfunction and AT inflammation. Here we report that mice deficient in GX 
sPLA2 are only modestly protected from HFD induced metabolic dysfunction. 
Body weights and percent fat mass were not significantly different between 
genotypes in either the LF or HF fed groups. This finding was unexpected given our 
previous data that GX KO mice had increased age-related weight gain and adiposity 
compared to control mice54. There are however conflicting reports regarding the effect of 
GX sPLA2 deficiency on body weight and adiposity122. It should also be noted that when 
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we previously reported increased weight gain and adiposity that these mice were singly 
caged at weaning54, potentially laying the foundation for inter-study variation in results. 
Additionally, these mice were fed normal rodent diet (Teklad Global 18% Protein Rodent 
Diet 2018S, 6.2% calories from fat, and absent of cholesterol) which has a very different 
dietary composition from the diets used in the current study in which mice were placed 
on low fat and high fat diets where 10% and 60% of the total calories were derived from 
fat respectively (Research Diets, D12450-B and D-12492).   
DIO results in metabolic derangements including glucose intolerance and 
peripheral insulin resistance. Previous studies from our laboratory suggest that GX KO 
mice are protected from age-related glucose intolerance. Hence, we hypothesized that GX 
sPLA2 deficiency would protect against HFD induced metabolic dysfunction. However 
the current findings suggest that GX sPLA2 deficiency exerts very modest and transient 
protection against HFD induced glucose intolerance and insulin resistance. In adipocytes, 
the insulin-dependent uptake of glucose is achieved through the translocation of glucose 
transporter type-4 (GLUT4) from intracellular storage vesicles to the plasma 
membrane123. Notably, deletion of adipose GLUT4 resulted in an ~53% reduction in 
whole-body insulin-stimulated glucose uptake and leads to marked insulin resistance in 
both the liver and skeletal muscle124. Interestingly, activation of the LXR has been shown 
to improve glucose tolerance in a model of DIO. This affect was attributed to the LXR 
dependent increase in glucose transporter type-4 (GLUT4) expression in AT but not 
skeletal muscle113. Conversely, mice deficient in LXRβ were glucose intolerant due to 
diminished glucose-stimulated insulin secretion125. However, LXRβ deficiency also 
appears to protect mice from diet or age-related weight gain. One way in which GLUT4 
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gene expression is controlled in AT is through activation of the nuclear receptor LXR113.  
Interestingly, GLUT4 gene expression is not regulated by insulin in AT, whereas 
treatment of mice with insulin and the LXR agonist T0901317 synergistically increased 
AT GLUT4 expression in vivo113. AT insulin-resistance, either as the result of 
hyperinsulinemia or HFD feeding, led to decreased insulin-dependent GLUT4 
translocation to the plasma membrane due to perturbations in the phosphatidylinositol 3-
kinase (PI3K)/AKT signaling axis126. We have recently shown that GX sPLA2 acts to 
negatively regulate LXR transcriptional activation in adipocytes54. Thus, it is feasible that 
any effects GX sPLA2 deficiency had on LXR dependent GLUT4 gene expression in AT 
would be negated by the decrease in insulin sensitivity in response to HFD. However, 
recent studies from our lab also suggest that GX sPLA2is capable of suppressing 
pancreatic insulin secretion, probably through the production of prostaglandin E2 (Shridas 
et al., unpublished data), a known inhibitor of GSIS in pancreatic islet cells. This 
observation is consistent with the fact that when compared with WT mice, GX KO mice 
were partially protected from HFD induced glucose intolerance after 8weeks of feeding 
with no differences in insulin sensitivity between genotypes during this time (Table 2). 
These findings suggest that the beneficial effects of GX sPLA2 deficiency on blood 
glucose levels after HFD feeding may be due to its role in regulating GSIS in the 
pancreas. 
The recruitment of inflammatory ATMs into AT in response to HFD is linked to 
the development of metabolic abnormalities including glucose intolerance and insulin 
resistance. Indeed, the absence of ATM recruitment to dysfunctional AT in response to 
HFD normalizes insulin sensitivity and blood glucose levels119,127. We have recently 
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shown in a model of angiotensin II induced abdominal aortic aneurism (AAA) formation 
that GX sPLA2-/-/apoE-/- (GX DKO) mice have reduced expression of the pan 
macrophage marker F4/80in the abdominal aorta when compared to apoE-/- control 
mice49. Therefore we investigated the possibility that GX sPLA2 deficiency may protect 
against ATM infiltration of AT in response to HFD. However, ATM content within the 
eAT of GX KO mice fed a HFD was not significantly different from that of HFD fed 
control mice. Notably, Wu et al.128 showed that ATM content is unchanged with age, they 
went on to argue that adipocytes and not stromal cells derived from adipose tissue of 
aged mice are responsible for the increases in AT inflammatory cytokine expression. 
However, other studies have shown that while total macrophage content is unchanged in 
aged mice when compared to young, the ATM subtype found in the AT of aged mice is 
altered but not clearly distinguishable as either M1 or M2 macrophages105. These findings 
suggest that, at least in mice, the mechanisms underlying AT inflammation and metabolic 
dysfunction associated with aging may be different from that of DIO. While GX 
sPLA2deficiency clearly protects against age-related glucose intolerance, ATM content 
and polarity has not been assessed in aged-GX KO mice. 
The increased expression of inflammatory cytokines in AT in response to DIO is 
a major contributor to AT insulin resistance. Several groups, including our own, have 
now demonstrated a role for GX sPLA2 in potentiating the inflammatory response in 
vivo43,129,130. However, GX sPLA2 deficiency did not protect mice from HFD-induced 
inflammatory cytokine production within the eAT. In fact, GX KO mice fed a HFD 
actually had significantly increased expression of TNF-α, compared to HFD fed control 
mice. However, this was also accompanied by a compensatory increase in IL-10 
54 
 
expression. This might be suggestive of increased macrophage infiltration in GX KO 
mice; however the F4/80 immunofluorescent staining and qRT-PCR data refute this 
possibility.  
The increased cytokine expression in the eAT of GX KO mice was unexpected 
given that GX sPLA2 deficiency in macrophages results in a reduced inflammatory 
response to LPS43. One possible explanation for the data is that GX KO mice fed a HFD 
have enhanced infiltration of lymphocytes into the eAT compared to control HFD fed 
mice. Flow cytometry studies by Penicaud et al. demonstrated that in mice, increased 
adiposity and in particular increased eAT mass was positively associated with enhanced 
T cell infiltration131,132. Visceral AT from obese humans is characterized by increased 
numbers of T and natural killer (NK) cells, likely accounting for the enhanced expression 
of IFNγ, and regulated upon activation, normal T-cell expressed and secreted 
(RANTES)133.  Importantly, T helper cell type-1 (Th1) derived cytokines are important 
modulators macrophage polarity. In particular, the Th1 derived cytokine, IFNγ may act to 
promote a “classically activated” M1 macrophage phenotype134. IFNγ deficient mice 
have reduced AT inflammation and decreased infiltration of ATMs in response to diet-
induced obesity, and this is associated with improved glucose tolerance compared to 
control mice135. Importantly, splenic CD4+ T cells isolated from GX DKO (GX sPLA2-/-
/Ldlr-/-) mice have an enhanced proliferative capacity and an exaggerated Th1 phenotype 
compared to CD4+ T cells from control Ldlr-/- mice. Moreover, flow cytometry 
experiments demonstrated an ~35% increase in IFNγ+ CD4+ T cells within the GX DKO 
CD4+ T cell population as a whole. Thus, when compared to control mice, enhanced Th1 
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derived cytokine production in GX KO mice may contribute to AT inflammation and 
metabolic dysfunction in the context of diet-induced obesity. 
A role for TLR4 in mediating DIO and insulin resistance has been previously 
reported101,136. Importantly, TLR4 deficiency has been shown to promote alternative 
activation of ATMs104. As previously mentioned, our lab reported that GX KO mice have 
reduced plasma inflammatory cytokine expression in response to LPS, likely due to 
blunted TLR4 signaling in macrophages. Lipid raft cholesterol content is known to 
influence TLR4 dependent inflammatory signaling137,138. It has recently been shown that 
increased gene expression of cholesterol efflux transporters ABCA1 and ABCG1can alter 
macrophage polarization toward M2 alternatively activated macrophages108. Interestingly, 
peritoneal macrophages isolated from GX KO mice have increased expression of LXR 
target genes ABCA1 and ABCG1 when compared to macrophages from WT mice. Thus, 
we hypothesized that GX sPLA2 deficiency may result in a shift toward less 
inflammatory M2 macrophages in the AT of mice fed a HFD. However, GX sPLA2 
deficiency did not predispose ATMs toward a less inflammatory M2 phenotype. It has 
been suggested that dietary fatty acids may act to inhibit LXR activation139. Accordingly, 
LXRα gene expression is decreased in the AT of obese Zucker rats140. To this extent, 
ABCA1 expression is decreased in monocyte-derived macrophages isolated from 
overweight and obese human subjects and this is associated with reduced cholesterol 
efflux capacity in these cells141. Thus, because the less-inflammatory phenotype seen in 
peritoneal macrophages isolated from GX KO mice likely hinges upon the LXR 
dependent efflux of intracellular cholesterol resulting in altered lipid raft lipid content43, 
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it reasonable to speculate that in a model of DIO where LXR activity is potentially down-
regulated, that the effect of GX sPLA2 deficiency may in fact be negligible. 
The sub-clinical, chronic low-grade inflammation associated with diet-induced 
obesity appears to be causally linked to the ensuing metabolic perturbations that follow, 
including glucose intolerance and insulin resistance. Infiltrating ATMs contribute 
significantly to AT inflammation in response to over-nutrition. ATMs of obese mice are 
predominately M1-like macrophages characterized by the up-regulation of inflammatory 
genes including TNFα and iNOS. However, ATMs of obese mice demonstrate 
remarkable plasticity such that M1-like macrophages with a distinctive 
F4/80+CD11b+CD11c+ phenotype prevail, while a lesser F4/80+CD11b+CD11c-  M2-like 
can also be found142. However, evidence in humans suggests that a spectrum of 
macrophage subtypes likely exists and cannot be clearly distinguished as either M1 or 
M2143,144. Indeed, a sub-population of ATMs has been identified in humans that express 
several cell surface markers typical of “alternatively activated” M2 macrophages, but are 
capable of producing high levels of inflammatory cytokines143. Thus, clearly any efforts 
to characterize distinct subpopulations of ATMs may be undermined but what has 
become increasingly recognized as a continuum of ATM phenotypes within the AT in 
response to obesity. 
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Figure 3.1: WT and GX KO mice have increased adiposity in response to HFD 
feeding. 
A. Male GX KO mice and littermate control mice were fed both LF and HF diets for 16 
weeks and weights were recorded every other week. B. Body composition was 
determined by echo-MRI every 4 weeks. 
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Figure 3.2: Plasma lipid levels of WT and GX KO mice after 16 weeks on diet.  
Mouse plasma was collected via cardiac puncture and analyzed for A. total cholesterol, 
B. triglycerides, and C. free fatty acids. Overall effects of diet are indicated by brackets. 
Date represents means ± SEM. ***P<0.001 
 
 
59 
 
Figure 3.3: GX KO mice are modestly protected against HFD-induced glucose 
intolerance.  
After mice were fasted for 6 hours, plasma glucose levels were measured before and after 
(every 30 minutes for 3 hours) intraperitoneal administration of either 1.5 g/kg glucose 
(weeks 0 and 4) or 2 g/kg glucose (weeks 8, 12 and 16). The data is represented as the 
area under the curve (AUC) in arbitrary units and is expressed as the mean ± SEM (n=5-
6). Overall effects of diet are designated by brackets. Significant differences between 
genotypes within each diet are designated by horizontal bars. Data represent the mean ± 
SEM. * P< 0.05, ** P<0.01 
 
 
60 
 
Figure 3.4: GX KO mice are not protected against HFD-induced insulin resistance.  
After mice were fasted for 6 hours, plasma glucose levels were measured before and after 
(every 30 minutes for 3 hours) intraperitoneal administration of 1 u/kg insulin. Data 
represents the AUC in arbitrary units and is expressed as the mean ± SEM. Overall 
effects of diet are designated by brackets. Significant differences between genotypes 
within each diet are designated by bars. Significant differences between genotypes within 
each diet are designated by horizontal bars. Data represent the mean ± SEM. * P< 0.05, 
** P<0.01 
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Figure 3.5: HFD feeding results in increased adipocyte hypertrophy in both WT and 
GX KO mice.  
A. Paraffin embedded epididymal adipose tissue (eAT) was stained using hematoxylin 
and eosin. B. The frequency distribution of adipocyte cell surface area of HF fed mice 
was analyzed. Frequency distribution represents 3 randomly chosen eAT sections from 3 
mice per group. C. The average adipocyte cell surface area from C. was determined.
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Figure 3.6: GX KO mice are not protected against HFD-induced macrophage 
infiltration of AT.  
WT and GX KO mice were fed LF and HF diets for 16 weeks at which point epididymal 
adipose tissue (eAT) was harvested for further analysis. A. RNA was isolated from eAT 
and qRT-PCR was performed using primers specific for pan macrophage marker F4/80 
(n=10-12). B. eAT was stained using an antibody specific for the pan-macrophage marker 
F4/80 and detected using immunofluorescence microscopy. Overall effects of diet are 
indicated by brackets. Date represents means ± SEM. ***p<0.001 
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Figure 3.7: GX KO mice are not protected against HFD-induced AT inflammation.  
qRT-PCR was performed on RNA isolated from the epididymal fat pads of mice using 
primers specific for genes IL-6, IL-10, MCP-1, IL-1β, and TNF-α. # P<0.05, ##P<0.01 
indicates significant difference between diets within a given genotype. Overall effects of 
diet are designated by brackets. Significant differences between genotypes within each 
diet are designated by horizontal bars. Data represent the mean ± SEM. *P<0.05, 
**P<0.01, P<0.001  
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Figure 3.8: GX sPLA2 deficiency does not alter the polarity of infiltrating ATMs.  
RNA was isolated from the epididymal fat pads after 16 weeks on diet and qRT-PCR was 
performed using primers specific for A. M1 (TNF-α, and iNOS) and B. M2 (MR, and 
arginase-1) macrophage markers (n=10-12). Overall effects of diet are designated 
by brackets. Significant differences between genotypes within each diet are designated 
by horizontal bars. Data represent the mean ± SEM. *P<0.05, ***P<0.001 
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Chapter 4 
Pro-GX sPLA2 processing by furin-like proprotein convertases: Implications for the 
regulation of adrenal steroidogenesis 
4.1 Introduction 
The secreted phospholipase A2 (sPLA2) family of enzymes hydrolyzes membrane 
phospholipids at the sn-2 position to liberate free fatty acids and lysophospholipids. The 
sPLA2 family is characterized by their low molecular weight (~14-18 kDa), requirement 
for millimolar concentrations of Ca2+, and utilization of a highly conserved catalytic 
histidine-asparagine dyad within their active sites. Eleven sPLA2 members have been 
identified (group IB, IIA, IIC, IID, IIE, IIF, III, V, X, XIIA, and XIIB PLA2-like protein 
that lacks catalytic activity) and placed into different groups based on the number and 
position of conserved cysteine residues that form disulfide bridges, generating a semi-
rigid three-dimensional structure (reviewed in1). Members of the sPLA2 family exhibit 
unique tissue distributions and disparate substrate specificities, reflecting their distinct 
roles in a range of physiological processes.  
Among the sPLA2s, Group X (GX) sPLA2 has the most potent hydrolytic activity 
toward zwitterionic phospholipids including phosphatidylcholine (PtdCho)38, the most 
abundant phospholipid in mammalian plasma membranes and lipoprotein particles. GX 
sPLA2 has a wide tissue distribution, including the small intestine, testes, brain, pancreas, 
lung, thymus, spleen, peripheral blood leukocytes, among others39,45.  Notably, GX 
sPLA2 appears to preferentially hydrolyze arachidonate and linoleate at the sn-2 position 
of PtdCho containing lipoproteins45,46.  The predilection of GX sPLA2 for arachidonate 
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has important consequences with respect to the generation of bioactive lipids. For 
example, GX sPLA2 has been implicated in the production of eicosanoids including 
PGE2, PGD2, leukotriene B4, and cysteinyl leukotrienes (cysLTs) in a Th2 cytokine-
driven mouse model of asthma41. 
The generation of C57BL/6 mice with targeted deletion of GX sPLA2 (GX KO 
mice) has led to new insights into novel mechanisms by which GX sPLA2 modulates 
physiological processes. Our laboratory reported that GX KO mice fed a normal rodent 
diet gain more weight and exhibit increased adiposity compared to wild-type mice54. We 
also determined that stromal vascular cells isolated from adipose tissue of GX KO mice 
accumulate significantly more triglyceride when induced to differentiate into adipocytes 
compared to cells from wild-type mice. Conversely, overexpression of GX sPLA2 in OP9 
pre-adipocytes resulted in a significant 50% reduction in triglyceride accumulation during 
differentiation into mature adipocytes, an effect that was associated with significantly 
reduced induction of adipogenic genes, including PPARγ, SREBP-1c, SCD1, and FAS. 
Activation of the liver X receptor (LXR), a nuclear receptor known to up-regulate 
adipogenic gene expression, was suppressed in OP9 cells when GX sPLA2was 
overexpressed, leading us to conclude that GX sPLA2 negatively regulates adipogenesis, 
possibly by suppressing LXR activation.  We also determined that GX sPLA2 suppresses 
LXR activation in macrophages, resulting in reduced expression of ATP-binding cassette 
transporters A1 (ABCA1) and G1 (ABCG1)53.  Consequently, macrophages from GX 
KO mice exhibit increased cellular cholesterol efflux and decreased cellular cholesterol 
content. GX sPLA2 is also expressed in adrenal cells, where it suppresses corticosteroid 
production through a mechanism that also appears to involve LXR.  Compared to wild-
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type mice, GX KO mice have significantly increased plasma corticosterone levels under 
both basal and adrenocorticotropic hormone (ACTH)-induced conditions.  The 
expression of steroidogenic acute regulatory protein (StAR), the rate-limiting protein in 
corticosteroid production, is significantly increased in adrenal glands from GX KO mice 
compared to wild-type adrenal glands.  Conversely, in the mouse adrenal Y1 cell line, 
overexpression of GX sPLA2 suppresses StAR expression. Results from luciferase 
reporter assays indicated that GX sPLA2 antagonizes StAR promoter activity and LXR-
mediated StAR promoter activation in adrenal cells.  In summary, results from gain-of-
function and loss-of-function studies in multiple tissues indicate that GX sPLA2 
modulates cellular metabolism by negatively regulating LXR target gene expression. 
Given the potent ability of GX sPLA2 to hydrolyze cell membranes and generate 
bioactive lipid mediators, its hydrolytic activity is likely under tight regulation. GX 
sPLA2 is one of only three sPLA2s produced as an inactive pro-enzyme, such that 
cleavage of an N-terminal pro-segment is necessary for its enzymatic activity45. Studies 
in transgenic mice with constitutive GX sPLA2 expression indicated that the inactive 
precursor is the predominant form expressed in most tissues under normal conditions58.  
However, enzymatically active GX sPLA2 was detected in the transgenic mice in tissues 
with inflammatory granulation, suggesting that proteolytic activation may occur during 
inflammation.  The N-terminal pro-segment of GX sPLA2 comprises eleven amino acids 
ending in a dibasic motif, suggesting cleavage by member(s) of the furin-like proprotein 
convertase (PC) family. Recently, Jemel et al.59 showed that in transfected human 
embryonic kidney (HEK 293) cells, the second residue within the dibasic doublet is 
necessary and sufficient for GX sPLA2 processing and hydrolytic activity. Furthermore, 
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using a panel of non-specific protease inhibitors, the involvement of PCs in GX 
sPLA2maturation and activation in 293 cells was confirmed. However, the identity of the 
individual PCs involved in GX sPLA2 processing in physiologically relevant tissues 
remained to be investigated. 
During the course of studying GX sPLA2 in adrenal cells, we noted significantly 
increased phospholipase activity secreted by Y1 cells stably transfected with a GX sPLA2 
expression construct, and to a lesser extent, control-transfected Y1 cells, in response to 
ACTH treatment. We reasoned that this increase in secretion reflected post-
transcriptional regulation of GX sPLA2, since the promoter driving recombinant GX 
sPLA2 expression in our cell system would not be expected to be regulated by ACTH53. 
Thus, mouse Y1 cells provided us a physiologically relevant model for understanding GX 
sPLA2 regulation. In this study we establish that pro-GX sPLA2 is proteolytically 
activated in Y1 adrenal cells by furin and PCSK6, two members of the PC family. We 
also provide evidence that PC-dependent proteolytic activation of pro-GX sPLA2 is 
enhanced under ACTH-stimulated conditions, suggesting a novel mechanism for 
regulating adrenal steroidogenesis.   
4.2 Results 
ACTH increases GX sPLA2 proteolytic activation in Y1 adrenal cells.  
To investigate mechanisms involved in regulating GX sPLA2 activity in adrenal 
cells, we generated mouse Y1 cells stably expressing GX sPLA2 fused to a C-terminal 3x 
FLAG sequence (Y1-GX). This chimeric construct allowed us to monitor GX sPLA2 
processing based on differences in the molecular weight of the inactive precursor, pro-
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GX (~15.2 kDa) and the mature form of the enzyme, m-GX (~13.9 kDa). In accordance 
with our previous findings55, ACTH treatment resulted in a modest but significant 
increase in the phospholipase activity secreted by control-transfected Y1 cells (Y1-C) 
(Figure 4.1A). The increased phospholipase activity in response to ACTH was highly 
significant in Y1-GX cells (Figure 4.1A). Associated with the increase in phospholipase 
activity in ACTH-treated Y1-GX cells was an increase in the ratio of m-GX:pro-GX 
sPLA2 in response to ACTH stimulation (Figure 4.1B). In the case of untreated Y1-GX 
cells, the ratio of m-GX:pro-GX sPLA2 present in the media was ~0.8:1. This contrasts to 
ACTH- treated cells, where the ratio of m-GX sPLA2:pro-GX sPLA2 was ~1.5:1. Thus, 
ACTH treatment resulted in an ~2-fold increase in the amount of m-GX sPLA2 relative to 
pro-GX sPLA2 present in the media. m-GX sPLA2 was not detected in cell lysates of Y1-
GX cells in either the absence or presence of ACTH (Figure 4.1C). Taken together, these 
results suggest that ACTH enhances the phospholipase activity secreted by Y1-GX cells, 
likely by increasing the proteolytic processing of pro-GX sPLA2, and that pro-GX sPLA2 
is the major, if not exclusive, form detected intracellularly.  
GX sPLA2 processing and activity are blocked by the furin-like proprotein 
convertase inhibitor RVKR.  
The family of furin-like proprotein convertases (PCs) has recently been 
implicated in the proteolytic activation of GX sPLA2 in transfected HEK 293 cells59. To 
investigate the role of PCs in regulating GX sPLA2proteolytic activation in mouse Y1 
adrenal cells, sPLA2 activity and pro-GX sPLA2 processing was assessed in Y1-GX cells 
treated with the PC inhibitor, Dec-RVKR-cmk (RVKR). After overnight incubation, both 
pro- and m-GX sPLA2 were detected in the media of vehicle-treated Y1-GX cells, and 
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ACTH treatment significantly increased the ratio of m-GX sPLA2:pro-GX sPLA2 
secreted by Y1-GX cells (Figure 4.2A). However, the increased processing of pro-GX-
sPLA2 in response to ACTH treatment was almost completely abolished in the presence 
of RVKR. This decrease in processing was accompanied by a significant reduction in 
sPLA2 activity secreted by the cells (Figure 4.2B). These results demonstrate a role for 
furin-like PCs in the proteolytic activation of GX sPLA2 in Y1 adrenal cells under both 
basal and ACTH-stimulated conditions.  
Furin and PCSK6 expression is increased in Y1 cells treated with ACTH.  
To identify candidate PCs that may be responsible for regulating GX sPLA2 
activity in adrenal cells, we quantified mRNA abundance for each member of the PC 
family in both Y1-Cand Y1-GX cells under basal and ACTH-stimulated conditions. 
Among the six candidate convertases, only four were expressed at appreciable levels (Ct 
value <35): furin, PCSK5, PCSK6, and PCSK7 (Figure 4.3). Ct values for PC1 and PC2 
were >35 in both basal and ACTH-treated cells. Interestingly, both furin and PCSK6 
mRNA abundance were significantly increased in response to overnight incubation with 
ACTH, consistent with the enhanced pro-GX sPLA2 processing. Unexpectedly, furin, 
PCSK5, and PCSK6 were increased in response to GX sPLA2 overexpression. Since furin 
and PCSK6 were up-regulated in response to ACTH, we further investigated the role of 
these PCs in regulating GX sPLA2 processing in Y1 cells. 
Pro-GX sPLA2 is proteolytically cleaved by furin and PCSK6.  
Previous reports characterizing the substrate specificity of PCs suggest some 
redundancy in functionality for some, but not all, targets (reviewed in61).  In order to 
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assess whether pro-GX sPLA2 is a substrate for furin and/or PCSK6 proteolytic 
activation, GX sPLA2 was co-expressed with either furin or PCSK6 in HEK293 cells. 
The ratio of m-GX sPLA2:pro-GX sPLA2 in media from HEK293 cells expressing GX 
sPLA2 alone was ~1:1(Figure 4.4A). Expression of either furin or PCSK6 resulted in an 
almost complete conversion of pro-GX sPLA2 to the mature form, indicating that pro-GX 
sPLA2 is a substrate for both PCs. m-GX sPLA2 was not detected in whole-cell lysates, 
indicating that furin- and PCSK6-dependent pro-GX sPLA2 processing occurs 
extracellularly in HEK 293 cells (Figure 4.4B).  
Both furin and PCSK6 contribute to pro-GX sPLA2 processing in Y1 cells.  
In order to determine if furin and/or PCSK6 mediate GX sPLA2proteolytic 
activation in adrenal cells, we employed small interfering RNAs (siRNAs) to suppress 
the expression of furin mRNA, PCSK6 mRNA, or both mRNAs. Both furin and PCSK6 
expression was effectively blunted ~75% using this approach (Figure 4.5A, B). Neither 
knockdown of furin or PCSK6 alone was able to significantly inhibit processing of GX 
sPLA2 secreted by Y1 cells (Figure 4.6A). However, knockdown of both furin and 
PCSK6 together resulted in a significant reduction in pro-GX sPLA2 cleavage. As 
expected, ACTH treatment significantly increased the ratio of m-GX sPLA2:pro-GX 
sPLA2 in the media compared to vehicle-treated cells (Figure 4.6B). However, enhanced 
pro-GX sPLA2 processing in response to ACTH was significantly decreased when furin 
and PCSK6 expression was suppressed. These findings strongly suggest that both furin 
and PCSK6 mediate GX sPLA2 processing in Y1 adrenal cells, and ACTH-induced 
increases in GX sPLA2 activity is at least partly due to up-regulation of these convertases. 
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The suppression of LXR activation by GX sPLA2 is enhanced when furin or PCSK6 
are overexpressed.  
We previously reported that GX sPLA2 inhibits LXR-mediated target gene 
activation through a mechanism that is dependent on its enzymatic activity53. Therefore, 
we investigated whether proteolytic activation of GX sPLA2 by furin or PCSK6 enhances 
GX sPLA2-dependent inhibition of LXR activation. As expected, GX sPLA2 
overexpression in HEK 293 cells suppressed the transcriptional activation of an LXR 
reporter construct under both basal and T0901317-treated conditions (Figure 4.7A, B). 
The inhibitory effect of GX sPLA2 on LXR activation was augmented when either furin 
or PCSK6 was co-expressed, indicating that GX sPLA2 processing by furin-like 
proprotein convertases may represent an important mechanism for regulating GX sPLA2-
mediated inhibition of LXR transcriptional activation. 
GX sPLA2-mediated suppression of steroidogenesis requires furin-like proprotein 
convertase activity.  
StAR plays a critical function in adrenal corticoid synthesis by delivering 
cholesterol to steroidogenic enzymes located in the inner mitochondrial membrane. 
Given its key role in corticosteroid production, StAR mRNA expression is under both 
positive and negative control by a variety of transcription factors, including LXR56.  
Given our previous finding that GX sPLA2 suppresses StAR expression in an LXR-
dependent manner55, it was of interest to investigate whether inhibiting PC activity 
impacted the ability of GX sPLA2 to regulate StAR, and hence steroid production in 
adrenal cells. As we reported previously, GX sPLA2 overexpression inhibited StAR 
protein expression in Y1 cells under both basal (Figure 4.8A) and ACTH-stimulated 
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conditions (Figure 4.8B). This inhibitory effect was abolished when cells were treated 
with RVKR at a dose that significantly reduced the amount of m-GX sPLA2 and sPLA2 
activity secreted by the cells (Figure 4.8 and Figure 4.10).  Collectively, these results 
indicate that furin-like proprotein convertases are required for GX sPLA2-mediated StAR 
regulation.   
We next assessed the effect of inhibiting PCs on steroid production in Y1-GX 
cells. Since Y1 cells do not express 21-hydroxylase, the enzyme required for conversion 
of progesterone to corticosterone145, progesterone levels in conditioned media were 
measured as an indicator of steroid production by these cells. As expected, treatment with 
increasing concentrations of RVKR resulted in a dose-dependent decrease in 
phospholipase activity secreted by Y1-GX cells (Figure 4.9A). Notably, progesterone 
production was reciprocally increased in response to increasing concentrations of RVKR 
(Figure 4.9B). In accordance with previous findings, GX sPLA2 overexpression 
significantly decreased progesterone production by Y1 cells under both basal and ACTH-
stimulated conditions (Figure 4.9C).  Treatment with RVKR ablated the inhibitory effect 
of GX sPLA2 on progesterone production, consistent with the conclusion that pro-GX 
sPLA2 processing by PCs is necessary for GX sPLA2 mediated suppression of 
steroidogenesis in Y1 cells. 
4.3 Discussion 
Furin-like PCs are calcium-dependent serine proteases that mediate the post-
translational processing and activation of numerous molecules important for tissue and 
whole-body homeostasis, such as cell surface receptors, pro-hormones, growth factors, 
matrix metalloproteinases, and adhesion molecules (reviewed in61). Perturbations in PC 
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activity have been implicated in multiple pathological conditions, including various 
endocrinopathies, infectious diseases, cancer, and Alzheimer’s disease, reflecting their 
fundamental role in diverse physiological processes. Here we identify pro-GX sPLA2 as a 
previously unrecognized substrate for two members of the PC family, furin and PCSK6, 
and provide evidence that proteolytic activation of pro-GX sPLA2 by PCs represents a 
novel mechanism for regulating glucocorticoid production in adrenal cells. 
The initial observation that prompted our study was the finding that 
phospholipase activity secreted by Y1-GX cells, and to a lesser extent Y1-C cells, was 
significantly increased when cells were stimulated by ACTH55.  We speculated that the 
increase in sPLA2 activity was due to enhanced conversion of both endogenous and 
ectopically expressed pro-GX sPLA2 to m-GX sPLA2 in ACTH-treated cells. A recent 
study by Jemel et al. provided strong evidence that pro-GX sPLA2 is proteolytically 
activated by a furin-like PC, although the identity of the specific PC(s) was not 
determined59. In an initial screening by RT-PCR we determined that four members of the 
PC family are expressed in Y1 adrenal cells, furin, PCSK5, PCSK6, and PCSK7. We 
conclude that both furin and PCSK6 play a major role in pro-GX sPLA2 processing in 
adrenal cells based on the following findings:  1) furin and PCSK6 mRNA abundance 
were both significantly induced by ACTH in Y1 adrenal cells; 2) pro-GX sPLA2 
processing and activation were blocked in ACTH-treated Y1 cells by the PC inhibitor 
RVKR; 3) co-transfection of pro-GX sPLA2 with either furin or PCSK6 significantly 
enhanced pro-GX sPLA2 processing in HEK 293 cells; and 4) pro-GX sPLA2 processing 
in adrenal cells was effectively blocked when the expression of both furin and PCSK6 
was suppressed.    
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Analysis of PC cleavage preferences and substrate specificities reveals 
considerable overlap among several members of the PC family146. However, caution 
should be taken when attempting to draw conclusions from studies using short unfolded 
peptides as substrates. Redundancy in furin substrate cleavage specificity has been 
described in the liver using an interferon-inducible Mx-Cre/loxP furin deficient mouse 
model147. Both soluble furin and PCSK6 are able to cleave pro-Nodal while bound to its 
co-receptor at the cell surface148,149. However, unique furin substrates including the iron 
regulatory protein, pro-hepcidin, and pro-bone morphogenic protein 10 (pro-BMP10) in 
the developing heart, have also been described150,151. Our data that suppression of both 
furin and PCSK6 by siRNA-mediated gene silencing is required in order to effectively 
block pro-GX sPLA2 processing provides direct evidence for redundancy, at least in Y1 
adrenal cells.  
In the current study, we only detected m-GX sPLA2 in the media, while only pro-
GX sPLA2 could be found in cell lysates. Furin is thought to process substrates in the 
trans-Golgi network, at the cell surface, and in endosomes; whereas PCSK6 dependent 
processing is believed to take place in the extracellular matrix. Notably, furin has been 
shown to process endogenously produced substrates exclusively at the cell surface. Pro-
ADAMTS9 was shown to be processed by furin at the cell surface before being secreted 
into the media152. Importantly, no evidence for mature-ADAMTS9 could be found in the 
cell lysates. Our findings are in contrast to a previous report that utilized cell-permeable 
and cell-impermeable inhibitors to define the cellular location of pro-GX sPLA2 
processing. In this study, the authors concluded that that pro-GX sPLA2 processing takes 
place both before and after secretion59. This conclusion was supported by the finding that 
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exogenously added pro-GX sPLA2 did not hydrolyze cell membranes. The reason for the 
discrepancy between these two findings is unclear; however, the possibility exists that PC 
dependent processing of pro-GX sPLA2 occurs coincident with secretion.   
The present study confirms previous findings from our laboratory documenting 
the role of GX sPLA2 in modulating adrenal steroidogenesis55. GX KO mice have 
increased plasma corticosterone levels under both basal and ACTH-induced stress 
conditions55. This phenotype is due at least partly to a direct effect of GX sPLA2 in the 
adrenal gland, since primary adrenal cells isolated from GX KO mice produce higher 
levels of glucocorticoids in response to ACTH compared to cells from wild-type mice55.  
We determined that GX sPLA2-mediated suppression of progesterone production in Y1 
adrenal cells is dependent on its hydrolytic activity, as evidenced by the fact that GX 
sPLA2, but not a catalytically inactive mutant lacking the active-site histidine residue, 
suppressed basal and ACTH-induced progesterone production in Y1 cells. Our finding 
that treatment with the PC inhibitor, RVKR, abolished GX sPLA2-dependent suppression 
of progesterone production under both basal and ACTH-stimulated conditions is 
consistent with previous observations that removal of the N-terminal pro-segment is 
necessary for GX sPLA2 hydrolytic activity39. Importantly, the derepression of 
progesterone production in Y1-GX cells treated with RVKR was associated with both 
decreased pro-GX sPLA2 processing and sPLA2 activity in conditioned media from these 
cells. Furthermore, RVKR resulted in significantly reduced sPLA2 activity secreted by 
Y1-C cells (data not shown), suggesting that upon processing, endogenous GX sPLA2 
contributes significantly to the phospholipase activity secreted by Y1 adrenal cells.   
Taken together, these data indicate that PCs proteolytically activate pro-GX sPLA2, 
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which in turn acts to suppress glucocorticoid production in adrenal cells. Although the 
mechanism has not been completely delineated, GX sPLA2 appears to negatively regulate 
adrenal glucocorticoid production through transcriptional suppression of StAR, most 
likely by reducing the activation of LXR55. StAR represents the rate-limiting protein in 
steroid hormone production, and many of the factors known to regulate steroidogenesis 
including LXR have their effect by targeting StAR153,154.  Results from the current study 
demonstrate that suppression of LXR reporter activation by GX sPLA2 is enhanced in the 
presence of either furin or PCSK6, and that inhibition of pro-GX sPLA2 processing by 
RVKR restores StAR protein expression in Y1-GX cells to levels comparable to Y1-C 
cells. Together, these findings suggest that processing of pro-GX sPLA2 by PCs is 
necessary for GX sPLA2-dependent suppression of LXR target gene activation.  
The body has evolved a complex regulatory network for finely tuning adrenal 
steroid production. Pituitary-derived ACTH stimulates the adrenals to produce 
glucocorticoids, which feedback on both the anterior pituitary and the hypothalamus to 
inhibit ACTH and corticotropin releasing hormone (CRH), respectively. Here we provide 
evidence for a negative feedback-loop in adrenal cells whereby ACTH increases PC 
expression, resulting in conversion of pro-GX sPLA2 to m-GX sPLA2, which in turn acts 
to suppress glucocorticoid production. What remains to be determined are the 
mechanism(s) responsible for turning off the activity of GX sPLA2. One potential 
pathway is the M-type sPLA2-receptor (sPLA2-R), which has been implicated in the 
lysosomal degradation of GX sPLA2. Chinese hamster ovary (CHO) cells overexpressing 
the sPLA2-R rapidly degraded GX sPLA2, resulting in a marked reduction in PGE2 
production compared to non-sPLA2 receptor expressing cells 36. A soluble form of the 
78 
 
sPLA2-R has been identified in mouse plasma that binds and inactivates GX sPLA2. The 
in vitro incubation of GX sPLA2 with plasma from wild-type mice but not sPLA2-R 
deficient mice decreases phospholipase activity37. We determined that the sPLA2-R is 
expressed in mouse adrenal glands and Y1 cells55. Interestingly, silencing sPLA2-R 
expression in YI-GX cells resulted in significantly reduced progesterone production, 
consistent with the possibility that the sPLA2-R internalizes and/or inactivates GX sPLA2, 
thereby reducing the magnitude of GX sPLA2’s suppressive effect55. 
Understanding the tissue-specific regulation of pro-GX sPLA2 processing will 
provide novel insights into the regulatory mechanisms governing physiological processes 
in which GX sPLA2 is thought to play a role. In addition to adrenal cells, studies in our 
lab documented that GX sPLA2 negatively regulates LXR target gene expression in 
macrophages and adipocytes, with significant consequences with respect to macrophage 
cholesterol efflux capacity53, macrophage-mediated inflammatory responses43, and 
adipocyte lipogenesis54. Given that both furin and PCSK6 are ubiquitously expressed61, it 
is tempting to speculate that these PCs are the predominant proteases involved in the 
conversion of pro-GX sPLA2 to m-GX sPLA2 in multiple cell types. Interestingly, furin 
mRNA expression and sPLA2 activity is significantly increased in J774 macrophages 
stably expressing GX sPLA2 when treated with lipopolysaccharide (unpublished data). 
Clearly, further studies are needed in order to solidify the roles of individual PCs in 
modulating GX sPLA2 activity in different tissues. 
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Figure 4.1:  
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Figure 4.1 (continued): ACTH increases pro-GX sPLA2 processing and 
phospholipase activity secreted by Y1 adrenal cells.  
Y1 adrenal cells were stably transfected with either a control expression vector (Y1-C) or 
a vector expressing 3X FLAG-tagged GX sPLA2 (Y1-GX) and then incubated with 0 or 
100nM ACTH for 20 hrs. A. Phospholipase activity in conditioned media was measured 
(n=6). B. Conditioned media (20μL) was immunoblotted using an anti-FLAG antibody 
(top); results from densitometric analyses are shown below (n=3). Data is expressed as 
the ratio of m-GX sPLA2:pro-GX sPLA2 in the media. C. Whole-cell lysates (10μg 
protein) were immunoblotted using anti-FLAG antibody (top) and anti-β-actin (bottom). 
For comparison, conditioned media from vehicle-treated Y1-GX cells (“media”) and 
lysates from Y1-C cells (Y1-C) were also analyzed. Data are means ± SEM and are 
representative of three independent experiments. * P<0.05, ** P<0.01, *** P<0.001 
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Figure 4.2: Pro-GX sPLA2 processing and activity are blocked by the furin-like 
proprotein convertase inhibitor RVKR.  
A. Y1-GX cells were incubated with 0 or 100nM ACTH in the presence or absence of 25 
μM RVKR for 20 hrs, at which time media was collected for immunoblotting with anti-
FLAG (top); results from densitometric analyses are shown below. Data are expressed as 
the ratio of m-GX sPLA2:pro-GX sPLA2 in the media. B. sPLA2 activity in the media 
was quantified. Data are means ± SEM and are representative of three independent 
experiments. ** P<0.01, *** P<0.001  
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Figure 4.3: ACTH increases furin and PCSK6 gene expression in adrenal cells.  
Both Y1-C and Y1-GX cells were incubated for 16 hr with either 0 or 100nM ACTH, and 
furin-like proprotein convertase gene expression was quantified by qRT-PCR (n=3). Data 
are means ± SEM and are representative of two independent experiments. *P<0.05  
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Figure 4.4: Pro-GX sPLA2 is proteolytically cleaved by furin and PCSK6.  
HEK293 cells were transiently co-transfected with 3X FLAG-tagged GX sPLA2 and 
either a control vector (GX-C) or a vector encoding furin (GX-F) or PCSK6 (GX-P). 
Cells were then incubated in fresh media for 24 hrs. A. Conditioned media was 
immunoblotted using anti-FLAG antibody (top); results from densitometric analyses are 
shown below. Data are expressed as the ratio of m-GX sPLA2:pro-GX sPLA2 in the 
media. B. Whole-cell lysates (10μg protein) were immunoblotted using anti-FLAG 
antibody (top) and anti-β-actin (bottom). Data are means ± SEM and are representative of 
two independent experiments. *** P<0.001  
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Figure 4.5: Small interfering-RNA mediated knockdown of furin and PCSK6.  
Y1-GX cells were transiently transfected with either control siRNA (scr) or siRNA 
targeting furin (F-si), PCSK6 (P-si), or both siRNAs (F/P-si). Furin (left) and PCSK6 
(right) mRNAs were quantified by qRT-PCR. Data are means ± SEM. (n=3). *** 
P<0.001 
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Figure 4.6: Pro-GX sPLA2 processing in mouse Y1 adrenal cells is dependent on 
furin and PCSK6 gene expression.  
A. Y1-GX cells were transiently transfected with either control siRNA (scr) or siRNA 
targeting furin (F-si), PCSK6 (P-si) or both siRNAs (F/P-si). B. Y1-GX cells transiently 
transfected with either control siRNA (scr) or siRNA targeting both furin and PCSK6 
(F/P-si). Cells were then incubated in fresh media containing either 0 or 100nM ACTH 
for 20 hr. Data (means ± SEM) are expressed as the ratio of m-GX sPLA2:pro-GX sPLA2 
in the media, and are representative of two independent experiments. * P<0.05, ** 
P<0.01 
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Figure 4.7: Pro-GX sPLA2 processing by furin or PCSK6 enhances GX sPLA2-
dependent inhibition of LXR-mediated gene activation.  
HEK 293 cells were transiently co-transfected with ptk-3X LXRE-luc reporter construct 
and vectors encoding mLXRα, mRXR, renilla-luciferase and either a control vector (293-
C) or a vector encoding GX sPLA2 in the absence  (293-GX) or presence of A. furin 
(293-GX+F) or B. PCSK6 (293-GX+P). Cells were then incubated in media containing 
either 0 or 1μM T0901317 for 24 hours prior to measurements of luciferase activity. Data 
are means ± SEM (n=4) and are representative of two independent experiments. * 
P<0.05, *** P<0.001 
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Figure 4.8: Inhibition of StAR protein expression by GX-sPLA2 is abolished by 
RVKR. 
Y1 cells were transiently transfected with either a control vector (Y1-C) or a vector 
encoding 3X-FLAG tagged GX sPLA2 (Y1-GX). Cells were then incubated in media 
containing 0 or 100nM ACTH and either DMSO vehicle or 25μM RVKR for 18 hours. 
Immunoblot analysis of total cell lysates was performed using antibodies specific for 
StAR and β-actin.  A. StAR and β-actin expression in Y1-C cells (lanes 1-4), Y1-GX 
cells (lanes 5-8), and Y1-GX cells treated with RVKR (lanes 9-12) in the absence of 
ACTH (top). Results from densitometric analyses (bottom) are expressed as the ratio of 
StAR:β-actin.  B. StAR and β-actin expression in Y1-C cells (lanes 1-4), Y1-GX cells 
(lanes 5-8), and Y1-GX cells treated with RVKR (lanes 9-12) in the presence of 100 nM 
ACTH (top).  Results from densitometric analyses (bottom) are expressed as the ratio of 
StAR:β-actin. Data are means ± SEM (n=3-4). * P<0.05 
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Figure 4.9: GX sPLA2-mediated inhibition of progesterone production by adrenal 
cells requires furin-like proprotein convertase activity.  
Y1 cells were transiently transfected with 3X-FLAG tagged GX sPLA2. Cells were then 
incubated with the indicated concentrations of RVKR for 20 hours. A. sPLA2 activity and 
B. progesterone levels were assayed in the media. C. Y1 cells were transiently transfected 
with either a control vector (Y1-C) or a vector encoding 3X-FLAG tagged GX sPLA2 
(Y1-GX). Cells were then incubated in media containing 0 or 100nM ACTH and either 
DMSO vehicle or 25μM RVKR for 20 hours. The concentration of progesterone in the 
media was measured and expressed relative to total cellular protein. Data are means ± 
SEM and are representative of two independent experiments (n=6). *** P<0.001 
 
89 
 
Figure 4.10: The PC inhibitor RVKR significantly reduces phospholipase activity 
and m-GX sPLA2 secreted by Y1 cells. 
Y1 cells were transiently transfected with either a control vector (Y1-C) or a vector 
encoding 3X-FLAG tagged GX sPLA2 (Y1-GX). Cells were then incubated in media 
containing 0 or 100nM ACTH in the presence or absence of 25μM RVKR for 20 hours. 
A. sPLA2 activity in the media was quantified and normalized to total cell protein. B. 
Conditioned media was immunoblotted with anti-FLAG antibody (top); results from 
densitometric analyses are shown below. Data are means ± SEM and are representative of 
three independent experiments (n=3). * P<0.05, ** P<0.01, ***P<0.01 
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Chapter 5  
Conclusions and future directions 
5.1 Introduction 
The phospholipase A2 (PLA2) family of enzymes consists of the cytosolic-PLA2s, 
the Ca2+- independent PLA2s (iPLA2s), the platelet-activating factor (PAF) acetyl 
hydrolases, and the small molecular weight secreted PLA2s (sPLA2s). All members 
within this family hydrolyze the sn-2 ester bond of glycerophospholipids liberating free 
fatty acids and lysophospholipids. Products generated from the hydrolysis of biological 
membranes provide an almost limitless number of bioactive lipid mediators with a 
diverse array of physiological functions. Thus, members of the PLA2 family have evolved 
unique substrate preferences based on their differences in biochemical structure, sub-
cellular localization, and Ca2+ dependence. GX sPLA2 is the most potent sPLA2 toward 
phosphatidylcholine, the most abundant phospholipid in mammalian cell membranes. GX 
sPLA2 has a wide tissue distribution represented in the diverse array of biological 
processes it is known to mediate. As we continue to develop our understanding of the 
function and regulation of GX sPLA2, it will likely provide valuable insight into the 
important physiological processes in which it is known to play a role. 
5.2 GX sPLA2 and AT inflammation and metabolic dysfunction 
The onset of obesity is characterized by the rapid expansion of adipose tissue 
(AT) depots, and subsequently, active AT remodeling. The remodeling of AT, defined as 
AT hypertrophy and hyperplasia, is associated with the recruitment of inflammatory 
adipose tissue macrophages (ATMs). The infiltration of ATMs appears to be causally 
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linked to the development of metabolic abnormalities including glucose intolerance and 
insulin resistance. We have previously demonstrated that GX KO mice have increased 
age-related weight gain, and this was due to an increase in overall adiposity54. Despite the 
increased fat mass, GX KO mice were protected from age-related glucose intolerance 
(Shridas et al., unpublished data).  Importantly, findings from our lab also indicated that 
macrophage mediated inflammatory responses are blunted in GX KO mice43. However, 
the role of GX sPLA2 in diet-induced obesity (DIO) had not been investigated. Hence, we 
endeavored to determine the role of GX sPLA2 in promoting macrophage mediated AT 
inflammation and metabolic dysfunction in a model of DIO. The current findings suggest 
that GX KO mice are only modestly protected from high fat diet (HFD) induced glucose 
intolerance. Moreover, GX KO mice were not protected from HFD induced insulin 
resistance. Most unexpectedly, markers of ATM infiltration and AT inflammation were 
unchanged in GX KO mice when compared to control mice. These findings suggest that 
whole-body GX sPLA2 deficiency has a negligible effect on HFD induced AT 
inflammation and metabolic dysregulation. 
5.2.1 Macrophage GX sPLA2 and AT inflammation 
The acquisition of C57BL/6 mice with a floxed GX sPLA2 allele may provide 
novel insight into the role of GX sPLA2 in promoting high fat diet (HFD)-induced 
metabolic dysfunction. Previous studies from our lab have defined a role for GX sPLA2 
in modulating macrophage inflammatory responses by altering lipid raft cholesterol 
content, resulting in blunted toll-like receptor (TLR) signaling43. Indeed, peritoneal 
macrophages isolated from GX KO mice have enhanced apoA1 mediated cholesterol 
efflux capacity, probably due to the increased expression of the liver X receptor (LXR) 
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target genes, ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1)53. When 
bone marrow-derived macrophages from ABCA1 deficient mice were stimulated with 
lipolysaccharide (LPS), they secreted less IL-10 and had enhanced inflammatory 
cytokine production compared to wild type (WT) macrophages, reminiscent of 
alternatively activated macrophages108. Thus, given the phenotype seen in GX KO 
macrophages, it would stand to reason that GX KO mice fed a HFD would be protected 
against HFD-induced ATM infiltration and AT inflammation. However, there were no 
differences in ATM infiltration or markers of AT inflammation GX KO and WT mice. 
Therefore, the question remains, why doesn’t GX sPLA2 deficiency result in decreased 
ATM accumulation or reduced AT inflammation in response to HFD?  
5.2.2 GX sPLA2 and the regulation of adipogenesis 
GX sPLA2 is produced by adipocytes, albeit to a lesser extent than 
macrophages54. However, our group has previously demonstrated that aged GX KO mice 
had enlarged fat cells compared to WT mice54. In vitro studies suggested that this 
phenotype could be attributed to GX sPLA2s ability to suppress LXR target gene 
expression, namely, SREBP-1c, DGAT1, FAS, and SCD-1. During obesity, the rapid 
expansion of AT is associated with adipocyte hypertrophy and hyperplasia. It has been 
suggested that the angiogenic response to rapidly expanding AT may be inadequate, and 
local hypoxia within the AT may contribute to AT inflammation during the early stages 
of disease155. Using expression levels of hypoxia inducible factor-1α (HIF-1α) as a 
surrogate marker, AT hypoxia has been demonstrated in models of genetic and diet 
induced obese mouse models156,157. AT hypoxia is accompanied be the expression several 
inflammatory cytokines including TNF-α, IL-1β, IL-6, PAI-1, and TGF-β among 
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others156,158. Furthermore, in vitro studies indicate that hypoxia may act to inhibit 
preadipocyte differentiation thus tipping the scale from a hyperplastic AT phenotype to 
one dominated predominately by hypertrophy159,160. It is unclear whether increased 
adipocyte cell mass in GX KO mice contributes to local hypoxia within the AT, thus 
potentiating the inflammatory response. Thus, is the blunted inflammatory macrophage 
inflammatory response in GX KO macrophages masked by the increased hypertrophy in 
GX KO adipocytes (Figure 5.1)? It would be of interest to learn if the adipocyte-specific 
deletion of GX sPLA2 would negatively impact metabolic function and AT inflammation 
in either aged of high fat fed mice. Conversely, would the macrophage-specific deletion 
of GX sPLA2 protect mice from HFD-induced AT inflammation and metabolic 
dysregulation in the absence of any effects on adipocyte function? 
5.2.3 Adrenal GX sPLA2 and metabolic dysfunction 
GX KO mice have increased plasma corticosterone levels under both basal and 
ACTH-induced stress conditions55. This phenotype was likely due the derepression of the 
steroidogenic acute regulatory protein (StAR), a known LXR target gene56. While the 
impact of hypercorticosteronemia on metabolic function in GX KO mice has not been 
defined, there is reason to believe that it could introduce confounding factors when 
attempting to interpret the role of macrophage-derived GX sPLA2 in high fat diet induced 
metabolic dysfunction  and AT inflammation. There is now evidence to suggest that 
hyperglucocorticoidism may contribute to the pathophysiology of the metabolic 
syndrome. Indeed, increased secretion of GCs in patients suffering from Cushing’s 
syndrome leads to central obesity, hyperglycemia, hyperlipidemia, glucose intolerance, 
and hypertension87. GCs have been shown to cause insulin resistance in skeletal muscle 
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but act to augment insulin signaling in subcutaneous fat depots161. In the liver, GC’s 
promote gluconeogenesis resulting in enhanced hepatic glucose output93,94. Thus, adrenal 
GX sPLA2 deficiency may be contributing to what is becoming recognized as a 
particularly convoluted metabolic phenotype. Therefore, the question remains, does 
adrenal GX sPLA2 deficiency promote glucoregulatory imbalances independent of its 
effects in other tissues? 
5.3 The GX sPLA2 regulatory network 
Previous work from our lab has demonstrated the role for GX sPLA2 in the 
regulation of glucocorticoid production in the adrenals. GX KO mice exhibited 
hypercorticosteronemia under both basal and ACTH-stimulated conditions. In vitro 
studies attributed this affect to GX sPLA2s ability to negatively regulate the liver X 
receptor (LXR) transcriptional activation of StAR, the rate-limiting protein involved in 
glucocorticoid production.  Therefore, understanding how GX sPLA2 is being regulated 
in the adrenals may provide valuable insight into the mechanisms governing adrenal 
steroidogenesis. In this study, we identified pro-GX sPLA2 as a novel substrate for PC 
mediated proteolysis in Y1 adrenal cells. We also demonstrated that proteolytic activation 
of pro-GX sPLA2 by PCs was necessary for GX sPLA2 dependent suppression of StAR, 
and subsequently, glucocorticoid production (Figure 5.2). These studies have set the stage 
for further investigation into the complex regulatory network surrounding GX sPLA2,not 
only in the adrenals but in other tissues where GX sPLA2 has been shown to play an 
important physiological role43,49,53-55.   
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5.3.1 ACTH dependent regulation of PCs in the adrenals 
  In the current study, we defined a role for furin and PCSK6 in the ACTH-induced 
proteolytic activation of pro-GX sPLA2 in Y1 adrenal cells. ACTH treatment of Y1 cells 
resulted in enhanced furin and PCSK6 gene expression. However, the regulatory 
mechanisms underlying the ACTH-dependent activation of furin and PCSK6 remain 
undefined. ACTH stimulation of G-protein coupled receptors (GPCRs) predominately 
results in the Gαs mediated production of cAMP and the subsequent activation of PKA. 
The Janus-kinase signal transducer (JAK2) has recently been implicated in ACTH/cAMP 
induced steroidogenesis80. Under either basal or ACTH-stimulated conditions, the JAK2 
dependent phosphorylation of the cAMP response element binding protein (CREB) 
prevented its proteosomal degradation, leading to increased transcriptional activation of 
StAR80.  In adrenocortical cells, stimulation with either angiotensin II or magnonol 
resulted in the JAK2 dependent transcriptional activation of StAR, mediated in part 
through a MAPK/ERK1/2 pathway162,163. Notably, JAK/STAT signaling has been 
implicated in the regulation of furin gene expression and release of soluble-BAFF (a 
member of the TNF ligand superfamily) in stimulated gangliosides164.  In HepG2 cells, 
transforming growth factor-β1 (TGF-β1) stimulation resulted in the ERK1/2 dependent 
increase in furin promoter activation and mRNA expression165. Similarly, ERK1/2 was 
involved in the enhanced furin expression in response to transferrin receptor activation166. 
Most notably, in Y1 adrenal cells, ACTH stimulation resulted in the increased 
phosphorylation of ERK1/2 and subsequently enhanced ERK1/2/MAPK activity167. The 
transcriptional regulation of PCSK6 is much less clearly defined, however sequence 
analysis of the 5’ flanking region identified several potential binding sites for 
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transcription factors including SP-1, AP-1, AP-2, PEA3, Ets-1, GHF-1, basic helix-loop-
helix (bHLH) proteins, and most notably CREB168. Therefore, ACTH stimulation of Y1 
cells may result in a multifaceted response leading to the activation of both cAMP-
dependent and independent (MAPK/ERK1/2) pathways, ultimately resulting in the CREB 
mediated up-regulation of PCs involved in the proteolytic cleavage of pro-GX sPLA2 
(Figure 5.3). 
 In the current study, we were able to show the up-regulation of PCSK6 mRNA in 
response to ACTH treatment of Y1 cells. However, the increase in mRNA abundance 
was relatively modest, and thus we cannot rule out the possibility that PCSK6 activity is 
also regulated post-translationally through the removal of its prosegment. PCs are 
produced as inactive precursors requiring two sequential cleavages of their prosegments 
in the endoplasmic reticulum and then in the trans-Golgi network. However, in Y1 
adrenal cells, PCSK5A has been shown to retain its prosegment at the plasma 
membrane65. However, treatment with either ACTH or 8-bromo-cyclic AMP results in 
the decreased detection of the prosegment at the cell surface and increased PCSK5A 
proteolytic activity as evidenced by the enhanced processing of PCSK5 substrates, Lefty, 
ADAMTS-4 endothelial lipase, and PCSK9. PCSK5A binds heparin sulfate 
proteoglycans (HSPGs) on the cell surface through interaction with its cysteine-rich 
domain (CRD)65. This interaction is thought to impart substrate specificity and facilitate 
the removal of the prosegment. Intriguingly, PCSK6 also interacts with HSPGs via its 
CRD and thus may be regulated in a similar fashion65.  Therefore, the post-translational 
regulation of PCSK6 may be yet another mechanism accounting for the enhanced pro-GX 
sPLA2 processing in response to ACTH (Figure 5.3). 
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5.3.2 Regulation of PCs in other tissues 
We have previously defined a role for GX sPLA2 in modulating macrophage 
inflammatory responses. The overexpression of GX sPLA2 results in augmented lipid raft 
cholesterol content and enhanced TLR4 mediated responses to LPS. However, it is 
unclear how GX sPLA2 is regulated in macrophages. Among the PC family members, 
furin and PCSK6 are among the most widely expressed61 and may therefore be 
responsible for pro-GX sPLA2 cleavage in tissues other than the adrenals. Preliminary 
data from our lab suggests that the phospholipase activity secreted into the media by J774 
macrophages stably expressing GX sPLA2 (J774-GX) is increased in response to LPS 
(Zahoor et al., unpublished data). Importantly, LPS treatment of J774-GX macrophages 
also results in enhanced furin gene expression (Zahoor et al., unpublished data). 
However, the intracellular mechanisms underlying the up-regulation of furin in response 
to TLR4 activation are unknown. In bone marrow derived granulocytes, the TLR4 
dependent shedding of TNF-receptor requires both p38 MAPK and furin169. The 
treatment of fibroblasts with tumor necrosis factor-α (TNF-α) results in increased furin 
activity and pro-MT1-MMP processing170. Using the human monocyte THP-1 cell line, it 
has been shown that PMA-induced macrophage differentiation is characterized by 
increased expression of furin and PCSK5, and enhanced pro-MT1-MMP processing171.  
Importantly, PMA-induced THP-1 differentiation resulted in the rapid, transient 
activation of MAPK signaling (ERK1/2, p38, JNK)172-174. Thus, MAPK signaling 
represents one potential mechanism underlying the regulation of PCs in macrophages and 
perhaps other relevant tissues where GX sPLA2 is known to play a role. 
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5.3.3 GX sPLA2-dependent up-regulation of PCs 
There is now evidence to suggest that PC substrates may enhance PC expression, 
in what would constitute a feed-forward loop. Furin has been identified as the 
predominant transforming growth factor-β (TGF- β) converting PC175.  Interestingly, in 
HepG2 cells, TGF-β receptor stimulation led to the cooperative up-regulation of both 
Smad signaling and p42/p44 MAPK pathways, resulting in increased nuclear 
translocation of Smad2 and furin gene transactivation165. Data from our lab suggests that 
Y1 adrenal cells stably expressing GX sPLA2 (Y1-GX cells) have significantly increased 
expression of select PCs, most notably, furin, PCSK6 and PCSK5, when compared to 
control transfected Y1 cells (Y1-C). Thus, PC up-regulation in response to enhanced GX 
sPLA2 expression may represent a mechanism ensuring adequate PCs are available to 
proteolytically activate pro-GX sPLA2. While the mechanisms governing the GX sPLA2 
dependent up-regulation of PCs is unclear, there is evidence to suggest that eicosanoids 
derived from membrane hydrolysis may play a role. Indeed, the cysteinyl leukotriene D4 
(CysLTD4) enhanced furin expression in HEK 293 cells expressing the CysLT1-
receptor176. Importantly, incubation of eosinophils with recombinant GX sPLA2 resulted 
in the production of CysLTs177. 
5.3.4 Post-transcriptional regulation of GX sPLA2 
Results from our lab suggest that ectopically-expressed GX sPLA2 mRNA 
abundance is increased in response to ACTH in Y1 cells. This finding likely indicates an 
increase in mRNA stability due to the fact that the CMV promoter-driven GX sPLA2 is 
unlikely to be transcriptionally regulated by ACTH-stimulation. Intriguingly, within the 
3’untranslated region (3’UTR) of GX sPLA2 there exists a highly conserved target 
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sequence for miR-19a (Figure 5.4). Recently, the dysregulation of miR-19a has been 
described in chronic inflammatory diseases including ulcerative colitis (UC)178. 
Moreover, the 3’UTR of TNF-α was recently identified as a miR-19a target179.  miR-19a 
expression levels were significantly reduced in the colons of both humans with ulcerative 
colitis (UC), and in dextran sodium sulfate (DSS) induced UC in rodent models178. Most 
notably, the decreased miR-19a levels are associated with significantly increased TNF- α 
in both human and rodent colon tissues. GX sPLA2 has been implicated in several 
chronic inflammatory diseases including asthma, rheumatoid arthritis, and atherosclerosis 
to name a few40,129,180. Thus, it is tempting to speculate that miR-19a may represent a 
novel mechanism by which GX sPLA2 mRNA stability can be altered.  
5.3.5 GX sPLA2 deactivation       
The potency with which GX sPLA2 hydrolyzes phosphatidylcholine infers there 
must be tightly controlled mechanisms regulating both the proteolytic activation of pro-
GX sPLA2 and perhaps of equal importance, the de-activation of mature-GX sPLA2 (m-
GX sPLA2). There is evidence to suggest that GX sPLA2 acts as a ligand for the sPLA2 
receptor (sPLA2-R) in Chinese hamster ovary (CHO) cells36. Furthermore, GX sPLA2 
binding to the sPLA2-R leads to increased GX sPLA2 degradation and diminished PGE2 
production36. Notably, studies from our lab indicate sPLA2-R silencing in Y1 cells stably 
expressing GX sPLA2 leads to decreased progesterone levels55. Thus, it is feasible to 
speculate that in the absence of sPLA2-R expression in Y1 cells more GX sPLA2 is 
available to suppress progesterone production. Alternatively, a soluble form of the 
sPLA2-R has been detected in mouse plasma where it binds and inactivates GX sPLA237. 
Indeed, in vitro incubation of GX sPLA2 with plasma from wild type, but not sPLA2-R 
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deficient mice, inhibits phospholipase activity37. Inhibitor studies in sPLA2-R expressing 
CHO cells revealed a role for matrix metalloproteinase’s (MMP’s) in the proteolytic 
cleavage and release of membrane-bound sPLA2-R37. However, the identity of the 
individual MMPs involved is unknown. Studies from our lab suggest that GX sPLA2 may 
increase the expression of MMPs in the abdominal aorta of mice receiving subcutaneous 
infusion of angiotensin-II (ang-II)49. Taken together, the MMP dependent release of 
soluble sPLA2-R from membranes could constitute a negative-feedback loop for limiting 
GX sPLA2 hydrolytic activity. 
5.3.6 GX sPLA2 dependent suppression of LXR 
GX sPLA2 dependent hydrolysis of membrane phospholipids results in the release 
of free fatty acids, most notably arachidonic acid (AA) and lysophosphatidylcholine 
(LysoPtdCho) Previous work by our lab has defined a role for GX sPLA2 as a negative 
regulator of liver X receptor (LXR) target gene expression43,53-55. In J774 macrophages, 
GX sPLA2 hydrolytic activity is required for suppression if the LXR target genes, ATP-
binding cassette A1 (ABCA1) and G1 (ABCG1). Importantly, the effect of GX sPLA2 on 
ABCA1 and ABCG1 can be mimicked with treatment of J774 macrophages with AA but 
not LysoPtdCho. However, indomethacin, a non-selective cyclooxygenase-1/2 inhibitor, 
has no effect on GX sPLA2 dependent inhibition of LXR target gene expression. Thus, 
GX sPLA2 mediated inhibition of LXR transcriptional activity does not appear to be 
dependent on the production of prostanoids. To date, the mechanism by which GX sPLA2 
negatively regulates LXR activation has not been defined.  
One possible mechanism by which GX sPLA2 may inhibit LXR is through its 
inhibitory phosphorylation. The protein kinase A (PKA) dependent phosphorylation of 
101 
 
LXR at serine 198181, which is embedded in a consensus MAPK phosphorylation 
sequence182. The phosphorylation of LXR prevents heterodimerization with retinoid X 
receptor (RXR) and recruitment of co-activator SCR-1, while enhancing recruitment of 
the co-repressor NcoR-1.Notably, in MA-10 mouse leydig cells, epoxygenase derived 
AA metabolites activated the cAMP/PKA signaling axis183. Similarly, PMA treatment 
results in the protein kinase C (PKC) dependent phosphorylation of LXR in HepG2 cells, 
leading to diminished SREBP-1c expression182. A route to PKC activation has been 
demonstrated in the ACTH dependent stimulation of GPCRs, resulting in the 
phospholipase C (PLC) dependent elevation of intracellular free Ca2+184. The PLC-
mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) produces two second 
messengers: inositol 1,4,5-trisphosphate (IP3),which releases Ca2+ from intracellular 
stores, and diacylglycerol (DAG), which activates protein kinase C (PKC). In the 
presence of phosphatidylserine and Ca2+, DAG activation of PKC triggers a kinase 
cascade mediated by Raf, MEK, and MAPKs185.  In HEK293 cells, treatment with low 
levels of AA (<0.5μM) results in increased membrane targeting of PKC from the 
cytosol186, likely facilitating PKC activation.  In a model of oxidative stress induced 
inflammation, GV and GIIA sPLA2 regulates the cPLA2α dependent release of AA 
leading to the downstream activation of PKC and ERK1/2187. In low-density lipoprotein 
receptor-related protein 1 (LRP1) deficient smooth muscle cells (SMCs) the 
phosphorylation and subsequent activation of cPLA2α was increased, and this was 
associated with decreased ABCA1 expression188. Notably, a cPLA2α inhibitor restores 
ABCA1 expression in LRP1 deficient SMCs188.  Thus, the GX sPLA2 dependent 
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activation of PKC and downstream effectors including ERK1/2/MAPKs may lead to the 
inhibitory phosphorylation of LXR (Figure 5.5).      
5.4 Concluding remarks 
 In conclusion, the tissue-specific deletion of GX sPLA2 may provide valuable 
insight into its role in HFD-induced metabolic dysfunction that was otherwise 
confounded by the whole-body knockout. Indeed, it may further our understanding of not 
only the macrophage-adipocyte crosstalk in the context of DIO, but may shed new light 
on the role of the adrenals in the metabolic derangements associated with DIO. 
The ability of GX sPLA2 to potently hydrolyze membrane phospholipids has necessitated 
the evolution of a complex regulatory network to govern its hydrolytic activity. We have 
identified pro-GX sPLA2 as a novel substrate for PCs in the adrenals. Moreover, we have 
identified a previously uncharacterized mechanism involved in the regulation of adrenal 
steroidogenesis. These findings have brought new questions to light. How are PCs being 
regulated in the adrenals? What PCs are involved in pro-GX sPLA2 processing in other 
tissues? What are the intermediates involved in GX sPLA2 dependent suppression of 
LXR transcriptional activity? As we continue to uncover the regulatory mechanisms 
surrounding GX sPLA2s activation, these findings will provide important insight into the 
complex physiological processes in which GX sPLA2 has been shown to play a role.  
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Figure 5.1: GX sPLA2 deficiency in adipocytes AND macrophages may cause 
opposing actions on DIO phenotype.  
GX KO in adipocyte results in increased adipocyte hypertrophy, potentially leading to 
more hypoxia, inflammatory cytokine production, and ATM recruitment. However, GX 
KO macrophages may be less responsive due to blunted TLR4 signaling. Thus, the 
absence of GX sPLA2 in both adipocytes and macrophages may cancel each other out 
with respect to the metabolic phenotype in a model of DIO.  
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Figure 5.2: ACTH enhances pro-GX sPLA2 processing in Y1 adrenal cells.  
ACTH stimulation of GPCRs results in the enhanced expression of PCs, furin and 
PCSK6, possibly through the cAMP-dependent activation of the CREB. Furin and 
PCSK6 are subsequently processed through the trans-Golgi network and secreted. 
Activation of PCs results in enhanced pro-GX sPLA2 processing and sPLA2 activity, 
leading to increased production of AA. AA metabolites then go on to inhibit LXR target 
gene expression, namely StAR. The decreased expression of StAR results in diminished 
GC production.   
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Figure 5.3: Proposed mechanism for the ACTH dependent increase in PC 
expression in Y1 cells.  
ACTH stimulation of GPCRs results in the activation of cAMP dependent and 
independent (ERK1/2/MAPK) pathways. In the presence of JAK2, PKA and ERK1/2 
converge to activate the CREB. CREB proceeds to increase the expression of PCs, furin 
and PCSK6.  
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Figure 5.4: Conserved miR-19a target sequence in the 3’untranslated region 
(3’UTR) of GX sPLA2 (Pla2g10).  
Highly conservedmiR-19a target sequence found in the 3’UTR of A. human GX sPLA2, 
B. mouse GX sPLA2, and C. rat GX sPLA2.  
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Figure 5.5: Proposed mechanism for GX sPLA2 dependent suppression of LXR.  
The activation of GX sPLA2 results in the cPLA2α dependent and independent production 
of AA. AA potentiates the GPCR dependent activation of PLC, resulting in enhanced 
intracellular free Ca2+ and PKC activation. PKC acts to suppress LXR/RXR 
heterodimerization associated with the recruitment of corepressors including NcoR-1 and 
the dissociation of coactivators such as SRC-1. Alternatively, AA may potentiate GPCR 
mediated activation of PKA, likewise suppressing LXR transcriptional activation.  
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